# Task 1: Cell Type Annotation Results

# Enrichment Interpretation / Annotation Report

## Interpretation Result

### Cluster: 0

### 1. Overview
The functional enrichment analysis of this post-treatment, non-major pathologic response (NMPR) LUSC sample reveals a dominant and highly specific T cell identity. The top enriched terms are exclusively cell type annotations (e.g., 'CD8+ T cell', 'T cell', 'Lymphocyte'), not signaling pathways or biological processes. The gene set is a core module of pan-T cell and TCR complex genes (TRAC, CD3D/E/G, TRBC1/2, CD2, PTPRC) co-expressed with the interleukin-7 receptor (IL7R) and cytokine IL32. This pattern defines a cluster of T lymphocytes, with the presence of both CD4+ (IL7R-high) and CD8+ lineage markers, and suggests states of activation, memory, and regulation. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor (TF) enrichment terms are provided in the list. However, key signaling receptors and cytokines among the marker genes act as upstream regulators. IL7R is a critical hub, receiving survival and homeostatic signals from IL7, which is a master regulator of T cell memory and persistence. The co-expression of the entire TCR-CD3 complex (CD3D, CD3E, CD3G, TRAC, TRBC1/2) indicates active TCR signaling, which drives downstream transcriptional programs via factors like NFAT, NF-κB, and AP-1. IL32 may function as an autocrine or paracrine modulator of T cell function and inflammation. Thus, the regulatory state is driven by integrated signals from the TCR (antigen engagement) and IL7R (homeostasis). 

### 3. Key Mechanisms
The analysis points to two intertwined mechanistic themes: 1) **T Cell Identity and Antigen Recognition**: The universal enrichment of T cell subtypes is mechanistically explained by the core TCR signaling apparatus (CD3 complex, CD2 co-stimulation) required for antigen-specific activation (supported by: T cell, CD8+ T cell, CD4+ T cell, Cytotoxic T cell). 2) **T Cell Differentiation and Homeostasis**: The concurrent enrichment of naive, memory, activated, and regulatory T cell states, all sharing IL7R and IL32, indicates a heterogeneous or transitional population where IL-7 signaling (via IL7R) is a key mechanism for maintaining T cell survival and memory potential (supported by: Naive T(Th0) cell, Memory T cell, Regulatory T(Treg) cell, Activated T cell). 

### 4. Crosstalk & Interactions
Crosstalk occurs between the antigen-driven TCR pathway and the cytokine-driven homeostatic pathway. TCR engagement (evidenced by CD3 complex expression) can upregulate IL7R expression, enhancing cell sensitivity to homeostatic cytokines. Conversely, IL-7 signaling can prime TCR responsiveness and promote survival of antigen-experienced cells. IL32, produced by activated T cells, may feed back to modulate local inflammation and T cell behavior. The network is centered on PTPRC (CD45), a critical phosphatase that regulates signaling thresholds for both TCR and cytokine receptors, integrating these signals to determine cell fate towards activation, memory, or regulation. 

### 5. Hypothesis
**What**: The analyzed cell cluster in post-treatment NMPR LUSC is defined by a core gene module of TCR components, IL7R, and IL32, leading to its annotation as a mixed-population of T cells with features of activation, memory, and regulation. **So What**: The persistence of this IL7R+ T cell state in a non-responding tumor after chemo-immunotherapy may represent a reservoir of tumor-reactive but dysfunctional or restrained lymphocytes. Their failure to achieve a major pathologic response could be due to an imbalance between pro-survival/homeostatic signals (IL7R) and full effector differentiation or to the co-presence of regulatory elements (e.g., suggested by 'Regulatory T(Treg) cell' enrichment). This state might be a target for therapeutic intervention to re-invigorate anti-tumor immunity. 

### 6. Narrative Draft
In post-surgical samples from LUSC patients with a non-major pathologic response (NMPR) to neoadjuvant camrelizumab plus chemotherapy, we identified a distinct cellular cluster characterized by a highly significant enrichment of T lymphocyte markers. This cluster's identity is defined by the coordinated expression of genes encoding the T cell receptor complex (TRAC, CD3D, CD3E, CD3G, TRBC1/2), the co-stimulatory molecule CD2, and the pan-leukocyte marker PTPRC (CD45). Notably, this core T cell signature is co-expressed with the interleukin-7 receptor (IL7R) and the cytokine IL32. Enrichment for terms spanning naive, memory, activated, and regulatory T cell states suggests a heterogeneous or transitional population. The presence of this IL7R+ T cell state in treatment-resistant tumors suggests that while T cells are present and potentially tumor-reactive, their functional program may be skewed towards persistence and homeostasis rather than cytotoxic effector function, possibly contributing to the observed lack of major pathological response. 

### 7. Refined Regulatory Network
Key Interactions:
  TCR Complex (CD3D/E/G with TRAC/TRBC1) -- Intracellular Signaling (e.g., LCK, ZAP70) (activation) - Core mechanism of antigen recognition; essential for T cell activation and downstream transcriptional changes.
  IL7 -- IL7R (binding/activation) - IL7R is a top marker; this interaction is the primary driver of T cell homeostatic survival and memory formation.
  IL7R -- STAT5 (activation) - Canonical downstream signaling of IL7R, promoting survival and memory gene expression.
  IL32 -- Inflammatory Response (modulation) - IL32 is a marker gene; it can act as a cytokine to modulate NF-κB and other pathways in T cells and the microenvironment.
  CD2 -- TCR Signaling (co-stimulation) - CD2 is a marker gene; it lowers the activation threshold of the TCR, integrating with antigen signal.
  PTPRC (CD45) -- Src-family kinases (LCK) (regulation) - Central regulator of TCR and cytokine receptor signaling; essential for setting activation thresholds.

**Network Evidence:**
The provided gene set forms a coherent protein-protein interaction network centered on the **TCR-CD3 complex** (CD3D, CD3E, CD3G, TRAC, TRBC1/2), which is a core signaling module for antigen recognition. **CD2** and **PTPRC (CD45)** are physically and functionally linked to this complex, modulating its signaling output. **IL7R** represents a parallel but interacting signaling module, receiving extrinsic survival signals. While not a complex in the structural sense, the co-expression of these genes defines a functional signaling module for 'T cell activation and homeostasis'. The network lacks specific effector molecules (e.g., IFNG, GZMB), consistent with a state focused on core identity and receptor signaling rather than terminal effector function. 

---

## Interpretation Result

### Cluster: 1

### 1. Overview
The enrichment analysis strongly indicates that the cell cluster is a B cell lineage population, specifically exhibiting features of follicular and naive B cells (supported by: Follicular B cell, Naive B cell, Mature B cell). Concurrent enrichment for T cell and natural killer cell terms, driven by shared marker genes like CD69 and LTB, suggests an activated lymphoid immune microenvironment. The top regulated genes (MS4A1/CD20, CD79A/B, BANK1) are canonical B cell markers, confirming this identity. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor (TF) enrichments were provided in the list. However, key regulated genes suggest potential upstream regulators. MS4A1 (CD20) is a target of PAX5, a master regulator of B cell commitment and identity. BANK1 is associated with B cell receptor (BCR) signaling and can modulate NF-κB activity. CD69 is an early activation marker induced by various stimuli, including NF-κB and NFAT signaling. Thus, inferred master regulators likely include PAX5 for B cell identity and NF-κB/NFAT for activation signals. 

### 3. Key Mechanisms
1. **B Cell Identity and Maturation:** The core signature is defined by BCR complex components (CD79A, CD79B) and pan-B cell markers (MS4A1, CD37), defining a mature B cell state (supported by: Follicular B cell, Naive B cell, Mature B cell).
2. **Lymphocyte Activation and Migration:** Enrichment of activation marker CD69 and chemokine receptor CXCR4 across B cell, T cell, and NK cell terms (e.g., Activated B cell, Memory CD8+ T cell, Natural killer cell) points to a shared activated/recruited phenotype. LTB (Lymphotoxin-beta) is a key cytokine for lymphoid tissue organization.
3. **Immune Cell Crosstalk:** The presence of genes like CD52 (pan-leukocyte) and LTB in multiple lymphoid cell type terms suggests this cluster exists within a dense lymphoid interaction network. 

### 4. Crosstalk & Interactions
The network is centered on B cells interacting with T cells and NK cells. Key crosstalk mechanisms include: 1) **LTB signaling** from B cells to stromal cells and other lymphocytes to organize lymphoid structures. 2) **CXCR4-CXCL12 axis** mediating recruitment and retention of both B and T cells. 3) **CD69**, an early activation marker, indicates recent stimulation potentially from shared microenvironmental signals (e.g., cytokine exposure). The co-enrichment of B and T cell states suggests these populations may be co-localized and reciprocally activated. 

### 5. Hypothesis
**What:** The analyzed cell cluster is a population of activated, tissue-resident B cells (follicular/naive phenotype) co-enriched with markers of T/NK cell activation.
**So What:** In the context of post-surgery, non-major pathologic response (NMPR) to neoadjuvant chemo-immunotherapy in LUSC, this B cell-rich, activated lymphoid signature may represent an organized but ineffective tertiary lymphoid structure (TLS) or residual follicular hyperplasia. Its persistence post-treatment suggests a tumor microenvironment that has resisted complete pathologic clearance, potentially through mechanisms of immune exclusion or dysfunctional lymphocyte priming, where B cells are present but not contributing to effective anti-tumor immunity. 

### 6. Narrative Draft
Functional enrichment analysis of a post-treatment, NMPR LUSC cluster revealed a dominant signature of B lymphocyte identity and activation. The most significantly enriched terms identified the population as follicular and naive B cells, defined by high expression of canonical markers including MS4A1 (CD20), CD79A, and CD79B. Notably, terms for T cells and natural killer cells were also enriched, largely driven by shared expression of early activation marker CD69 and the cytokine LTB. This co-expression pattern suggests a microenvironment containing multiple interacting, activated lymphoid lineages. In the setting of non-major pathologic response following neoadjuvant camrelizumab and chemotherapy, the persistence of this activated yet non-tumoricidal lymphoid aggregate may indicate the formation of tertiary lymphoid structures that have failed to mature into effective anti-tumor immune hubs, representing a potential mechanism of adaptive resistance. 

### 7. Refined Regulatory Network
Key Interactions:
  PAX5 -- MS4A1 (activation) - PAX5 is a master transcriptional regulator of B cell lineage commitment and directly activates MS4A1 (CD20) expression, defining B cell identity.
  BCR (CD79A/CD79B complex) -- BANK1 (binding/activation) - BANK1 is an adaptor protein that interacts with the BCR complex and modulates downstream signaling, including calcium mobilization.
  BANK1 -- NF-κB (modulation) - BANK1 can regulate IP3R-mediated calcium release, which influences NF-κB activation pathways downstream of BCR engagement.
  NF-κB / NFAT -- CD69 (activation) - CD69 is an early activation-induced gene in lymphocytes, and its promoter contains binding sites for NF-κB and NFAT, linking activation signals to the observed phenotype.
  LTB -- LTBR (binding) - LTB (lymphotoxin-beta) forms a membrane-bound complex that signals through LTBR on stromal cells, critical for lymphoid tissue organization and chemokine production (e.g., CXCL13).
  CXCR4 -- CXCL12 (binding) - CXCR4 expression on B and T cells mediates recruitment and retention within lymphoid niches in response to stromal-derived CXCL12, explaining its presence in multiple enrichment terms.
  CD52 -- Immune cell density (marker) - CD52 is a highly expressed pan-lymphocyte marker; its high signal reflects the overall high immune cell content and supports the 'Immune cell' enrichment term.

**Network Evidence:**
The core protein complex is the B Cell Receptor (BCR), formed by the membrane immunoglobulin non-covalently associated with the signaling heterodimer CD79A and CD79B, both highly upregulated. BANK1 is an adaptor known to bind to the BCR and modulate its signaling output. The network is extended by paracrine signaling modules: the LTB-LTBR axis is a key organizer of lymphoid stroma, and the CXCR4-CXCL12 axis mediates cell homing. CD69 acts as a convergent node for activation signals from various receptors (TCR, BCR, cytokine receptors), integrating the activated state across lymphoid cell types. 

---

## Interpretation Result

### Cluster: 2

### 1. Overview
The functional enrichment analysis reveals that the cluster is overwhelmingly dominated by myeloid-lineage immune cells, specifically macrophages and closely related cell types. The top enriched terms are all cell identity annotations (Myeloid cell, Macrophage, Tumor-associated macrophage (TAM), M2 macrophage, Dendritic cell, etc.), indicating the cluster's core cellular phenotype. The universal marker set (C1QB, C1QA, FCGR3A, MS4A6A, TYROBP, CD14, FCER1G, CD163, C1QC, AIF1) defines a population with strong complement activation, phagocytic receptor expression, and M2-like/TAM features. This profile is characteristic of a resident or tumor-infiltrating myeloid population in the post-treatment, non-major pathologic response (NMPR) lung squamous cell carcinoma (LUSC) microenvironment. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor (TF) enrichments were provided in the top terms list. However, key signaling hubs within the marker gene set can infer potential upstream regulators. TYROBP (DAP12) is a critical transmembrane adaptor protein that pairs with activating receptors like TREM2 and SIGLEC family members, often driving a pro-survival, immunomodulatory transcriptional program in macrophages. The co-expression of FCER1G (FcRγ), another ITAM-bearing adaptor, suggests signaling through multiple immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors. These adaptors likely activate downstream master regulators like PU.1 (SPI1), C/EBP family members, and MITF, which are known to control the expression of many of the marker genes (e.g., CD14, FCGR3A, CD163, C1Q genes). The strong complement component (C1Q) signature may also be regulated by Interferon Regulatory Factors (IRFs) and STAT family TFs in response to tumor-derived signals. 

### 3. Key Mechanisms
The analysis points to three major, interlinked functional modules: 1) **Phagocytosis and Immune Complex Clearance**: Supported by high expression of complement components (C1QA, C1QB, C1QC) and Fc receptors (FCGR3A/CD16, FCER1G). This module is involved in opsonization and clearance of antibody-coated cells or cellular debris. 2) **M2-like/TAM Polarization**: Supported by terms 'Tumor‐associated macrophage (TAM)' and 'M2 macrophage', and the expression of CD163 (hemoglobin scavenger receptor) and MS4A6A. This indicates an immunoregulatory, tissue-remodeling, and pro-tumorigenic phenotype. 3) **Innate Immune Sensor and Adaptor Signaling**: Supported by the universal presence of TYROBP and FCER1G, which are central signaling hubs for a plethora of activating receptors on myeloid cells, linking surface sensing to intracellular responses like phagocytosis, cytokine production, and cell survival. 

### 4. Crosstalk & Interactions
These mechanisms are highly interconnected. ITAM signaling via TYROBP/FCER1G (from receptors like TREM2 or CLECs) can directly enhance phagocytic capacity and promote an M2-like transcriptional state. The products of phagocytosis, in turn, can further reinforce M2 polarization. The C1Q complement proteins, often secreted by TAMs, can opsonize targets for clearance via the same FCGR3A receptor, creating a feed-forward loop. Furthermore, the 'Dendritic cell' and 'cDC2b' annotations suggest potential plasticity or a shared progenitor state with dendritic cells, where this population might retain some antigen-presentation capabilities (hinted by FCER1G and AIF1/IBA1) while being predominantly skewed toward macrophage/TAM functions. 

### 5. Hypothesis
**What**: The cluster is a post-treatment, M2-polarized Tumor-Associated Macrophage (TAM) population, defined by a core gene module of complement production (C1Q), phagocytic receptors (FCGR3A, CD163), and innate immune adaptors (TYROBP, FCER1G). **So What**: In the context of neoadjuvant camrelizumab (anti-PD-1) + chemotherapy in LUSC patients with a Non-Major Pathologic Response (NMPR), the persistence and dominance of this TAM state post-surgery suggests a mechanism of resistance. This population may contribute to an immunosuppressive tumor microenvironment by clearing antibody-opsonized cells, promoting tissue repair that favors residual tumor survival, and potentially attenuating adaptive anti-tumor immunity, thereby limiting the efficacy of immunotherapy. 

### 6. Narrative Draft
Single-cell analysis of post-surgical samples from non-responder (NMPR) LUSC patients treated with neoadjuvant camrelizumab and chemotherapy identified a dominant myeloid cluster with a highly consistent signature. Functional enrichment unequivocally annotated this population as myeloid cells, specifically macrophages and tumor-associated macrophages (TAMs) (supported by: Myeloid cell, Macrophage, Tumor‐associated macrophage (TAM), M2 macrophage). The universal marker set, including C1QA/B/C, CD163, CD14, and FCGR3A, delineates a state specialized for phagocytosis and immune complex clearance. Co-expression of key signaling adaptors TYROBP and FCER1G points to active engagement of ITAM-coupled receptors, which are known to drive immunomodulatory programs. The strong enrichment for M2/TAM phenotypes, coupled with the post-treatment, NMPR context, suggests this macrophage population may represent a therapy-resistant, pro-tumorigenic niche that persists after combined ICB and chemotherapy, potentially contributing to residual disease by suppressing effective anti-tumor immunity and promoting a wound-healing microenvironment. 

### 7. Refined Regulatory Network
Key Interactions:
  TYROBP -- FCGR3A (signaling_adaptor_for) - TYROBP (DAP12) is a well-characterized ITAM-bearing adaptor that pairs with and signals for activating receptors like TREM2, which can regulate macrophage phagocytic function and polarization, indirectly supporting FCGR3A-mediated activity.
  TYROBP -- CD163 (regulatory_link) - Signaling through TYROBP-associated receptors (e.g., TREM2) is known to promote anti-inflammatory/M2 macrophage polarization, of which CD163 is a canonical marker.
  FCER1G -- FCGR3A (signaling_synergy) - FCER1G (FcRγ) is another ITAM adaptor that can pair with various Fc receptors and other activating receptors; its co-expression with FCGR3A suggests a broad capacity for ITAM-mediated signaling in response to opsonized targets.
  C1QB -- FCGR3A (ligand_receptor) - The complement component C1q (composed of C1QA, C1QB, C1QC) can opsonize targets. FCGR3A (CD16a) is an Fc receptor that binds the Fc portion of antibodies but is also involved in the phagocytic clearance of complement-opsonized material, indicating functional crosstalk.
  TYROBP -- CD14 (co-regulated_module) - CD14 (LPS co-receptor) and TYROBP are both hallmark genes of myeloid cells and are often co-regulated by master transcription factors like PU.1 (SPI1), representing a core myeloid differentiation module.
  TYROBP -- AIF1 (functional_association) - AIF1 (Iba1) is a calcium-binding protein critical for macrophage motility and phagocytosis. Its expression is tightly linked to macrophage activation states that are regulated by ITAM signaling pathways involving adaptors like TYROBP.

**Network Evidence:**
The refined network centers on two core protein complexes/signaling modules: 1) The **ITAM Adaptor Module**, comprising TYROBP and FCER1G. These are not direct interactors but represent parallel, central hubs that transduce signals from numerous cell surface receptors (e.g., TREM2-TYROBP, CLEC-FCER1G) to Syk kinase, driving phagocytosis, cytokine production, and survival. Their universal presence in the marker set indicates this is a fundamental signaling apparatus of the cluster. 2) The **Phagocytic Synergy Module**, linking the secreted opsonin C1Q complex (C1QA/B/C) to the phagocytic receptor FCGR3A. This represents a key effector function: the clearance of complement-coated targets. The network is further supported by the co-expression of CD14 and AIF1, which are functionally critical for innate immune sensing and macrophage motility, respectively, completing the picture of a highly active, tissue-resident phagocytic cell. 

---

## Interpretation Result

### Cluster: 3

### 1. Overview
The enrichment analysis identifies a dominant B cell lineage signature, specifically a plasma cell/plasmablast state, in post-treatment, non-major pathologic response (NMPR) LUSC samples. The top enriched terms (Plasma cell, Plasmablast, Antibody-secreting cell) and the highly upregulated genes (e.g., IGHG1/3/4, JCHAIN, MZB1, XBP1) collectively point to an active humoral immune response characterized by antibody production and secretion. This is further supported by the presence of genes critical for endoplasmic reticulum (ER) expansion and the unfolded protein response (UPR) to handle high immunoglobulin output. 

### 2. Regulatory Drivers (TFs/Hubs)
The key inferred master regulator is XBP1 (X-box binding protein 1), a transcription factor central to plasma cell differentiation and the UPR. Its significant upregulation (Log2FC: 3.05) and presence in multiple enriched terms (Plasma cell, Plasmablast, Antibody-secreting cell) strongly suggest it is driving the transcriptional program for ER biogenesis (supported by genes like SEC11C, SSR4, DERL3) and immunoglobulin heavy chain production (IGHG1/3/4). While not listed as an enriched TF term itself, XBP1 is a well-established driver of the observed phenotype. 

### 3. Key Mechanisms
Two major, interlinked biological mechanisms are identified: 1) **Terminal B Cell Differentiation & Antibody Secretion**: This is defined by the expression of immunoglobulins (IGHG1, IGHG3, IGHG4), the J chain (JCHAIN) for IgA/IgM polymerization, and the plasma cell-specific chaperone MZB1. 2) **Secretory Machinery & ER Stress Response**: To support high-rate antibody secretion, cells upregulate genes involved in ER function and protein processing, including SEC11C (signal peptidase), SSR4 (translocon component), and DERL3 (ER-associated degradation). The enrichment of XBP1 ties these mechanisms together, as it transcriptionally activates both immunoglobulin genes and ER expansion machinery. 

### 4. Crosstalk & Interactions
The crosstalk is intrinsic and forms a coherent feed-forward loop. The initial commitment to plasma cell fate (potentially driven by external signals like BLIMP1, not in gene list) leads to XBP1 activation. XBP1 then simultaneously upregulates immunoglobulin genes, increasing the protein-folding load in the ER, and upregulates the ER machinery (SEC11C, SSR4) to handle this load. MZB1 operates at the nexus, facilitating immunoglobulin assembly within the ER. This creates a self-reinforcing network dedicated to maximizing antibody output. 

### 5. Hypothesis
**What**: A cluster of cells in post-treatment NMPR LUSC exhibits a strong plasma cell/antibody-secreting phenotype. **So What**: The presence of this active, differentiated humoral immune response in patients who did not achieve a major pathologic response (NMPR) suggests that the mere induction of antibody-secreting cells is insufficient for tumor clearance in this context. This may indicate a functionally restricted or spatially ineffective B cell response, potentially contributing to, rather than overcoming, treatment resistance. 

### 6. Narrative Draft
Single-cell analysis of post-treatment, non-responding (NMPR) LUSC tumors revealed a distinct cell state characterized by a profound plasma cell and plasmablast signature. This is evidenced by the marked upregulation of immunoglobulin genes (IGHG1, IGHG3, IGHG4, JCHAIN), the plasma cell-specific factor MZB1, and key components of the secretory pathway (SEC11C, SSR4, DERL3). Critically, the transcription factor XBP1, a master regulator of the unfolded protein response and plasma cell differentiation, was also upregulated, providing a mechanistic driver for the observed phenotype. The co-enrichment of terms for 'Antibody-secreting cell' and ER-associated genes underscores a functional program dedicated to high-volume antibody production. The persistence of this active humoral immune compartment in non-responders post-chemotherapy-ICB suggests that the qualitative features, localization, or antigen specificity of the antibody response may be a determinant of therapeutic efficacy, warranting further investigation into the spatial architecture and clonality of B cell responses in resistant tumors. 

### 7. Refined Regulatory Network
Key Interactions:
  XBP1 -- IGHG1 (activation) - XBP1 is a known transcriptional activator of immunoglobulin heavy chain genes during plasma cell differentiation.
  XBP1 -- SEC11C (activation) - XBP1 drives ER biogenesis and upregulates components of the secretory pathway, including signal peptidase complex members.
  XBP1 -- SSR4 (activation) - XBP1 upregulates ER translocon components to increase protein translocation capacity.
  MZB1 -- IGHG1 (chaperone_binding) - MZB1 is an ER-resident chaperone that specifically facilitates the assembly and secretion of IgM and IgG.
  DERL3 -- Unfolded Protein (degradation) - DERL3 is part of the ER-associated degradation (ERAD) machinery, a downstream component of the XBP1-driven UPR essential for managing misfolded proteins during high secretory demand.
  JCHAIN -- IGHG1/IGHG3/IGHG4 (polymerization) - JCHAIN links immunoglobulin monomers to form polymeric IgA or IgM, a key functional output of plasma cells.

**Network Evidence:**
The network centers on two functional modules: 1) The **XBP1 Transcriptional Module**, where XBP1 acts as a hub, directly activating target genes for immunoglobulins (IGHG1) and ER machinery (SEC11C, SSR4). 2) The **ER Protein Handling Complex**, comprising the SEC11C signal peptidase complex (for cleaving signal peptides), the SSR translocon (for protein import), the MZB1 chaperone (for immunoglobulin assembly), and the DERL3-containing ERAD complex. These modules are not isolated; the output of the XBP1 module (increased immunoglobulin synthesis) directly creates the substrate for the ER handling module, forming an integrated system for antibody production. The physical interaction between MZB1 and immunoglobulin subunits is a critical node ensuring efficient secretion. 

---

## Interpretation Result

### Cluster: 4

### 1. Overview
The enrichment results indicate a dominant epithelial cell identity program in this post-treatment, non-major pathologic response (NMPR) LUSC sample. The top signatures correspond to specific lung epithelial cell states, including basal (SOX2, KRT6A, KRT19, GPX2), acinar-like (AKR1C1-3), and luminal (KRT19, GPX2) phenotypes. This suggests the persistence or emergence of a heterogeneous, potentially primitive or regenerative, epithelial compartment after neoadjuvant chemo-immunotherapy in non-responding tumors. 

### 2. Regulatory Drivers (TFs/Hubs)
SOX2 is the primary transcriptional regulator identified (Basal cell signature). As a master regulator of stemness and basal cell fate in squamous epithelia, its high expression likely drives the basal-like phenotype and may contribute to a less differentiated, therapy-resistant state. The AKR1C enzyme family (AKR1C1, AKR1C2, AKR1C3), while not classic TFs, are key metabolic regulators acting as upstream effectors by modulating steroid and prostaglandin metabolism, potentially influencing cell survival and inflammatory signaling. 

### 3. Key Mechanisms
Two major intertwined biological themes are identified: 1) **Squamous Epithelial Identity and Plasticity**: Defined by high expression of basal (KRT6A, SOX2), luminal (KRT19), and shared (GPX2) cytokeratins. This co-expression pattern suggests a transitional or hybrid cell state with features of both basal and luminal lineages, often associated with regenerative capacity and plasticity. 2) **Metabolic Adaptation and Detoxification**: Centered on the aldo-keto reductase AKR1C family, which is involved in metabolizing steroids, prostaglandins, and lipid aldehydes. This module may protect cells from oxidative stress and chemotherapy-induced toxic metabolites (e.g., aldehydes), and can also influence intra-tumoral hormone signaling. GPX2 further supports an antioxidant defense mechanism. 

### 4. Crosstalk & Interactions
A core regulatory network likely exists where SOX2, a transcription factor, sustains the expression of basal cytokeratins (KRT6A) and may influence GPX2. Concurrently, the AKR1C-driven metabolic module could generate a protective, low-stress microenvironment that supports the survival of these SOX2+ epithelial cells. The shared gene GPX2 represents a point of convergence, linking antioxidant defense (a metabolic function) to epithelial cell state maintenance. The AKR1C enzymes, by regulating bioactive lipid mediators like prostaglandins, could also indirectly modulate inflammatory signals in the tumor microenvironment, potentially impacting immune cell activity. 

### 5. Hypothesis
**What**: The post-treatment NMPR LUSC cluster is enriched for signatures of basal, acinar-like, and luminal epithelial cells, driven by SOX2 and an AKR1C/GPX2-mediated detoxification program. **So What**: This specific co-expression pattern identifies a therapy-resistant epithelial cell state characterized by lineage plasticity (basal-luminal features) and enhanced metabolic detoxification. We hypothesize that this state represents a persistent, adaptive tumor cell population that survives neoadjuvant camrelizumab + chemotherapy by leveraging stemness-associated transcription (SOX2) and a dual chemical/oxidative stress defense system (AKR1C, GPX2), thereby contributing to non-response (NMPR). 

### 6. Narrative Draft
In post-surgical samples from LUSC patients with a non-major pathologic response (NMPR) to neoadjuvant camrelizumab plus chemotherapy, we identified a distinct epithelial cell state defined by co-enrichment of basal, acinar-like, and luminal signatures. This state is molecularly characterized by high expression of the stemness-associated transcription factor SOX2, basal cytokeratin KRT6A, luminal cytokeratin KRT19, and the antioxidant enzyme GPX2. A parallel, strongly upregulated module involves three members of the aldo-keto reductase family (AKR1C1, AKR1C2, AKR1C3), enzymes involved in steroid, prostaglandin, and reactive aldehyde metabolism. The concurrent activation of a SOX2-driven epithelial identity program and an AKR1C/GPX2-mediated detoxification pathway suggests a coordinated adaptive strategy. This hybrid cell phenotype, exhibiting features of both basal progenitor and specialized luminal cells, may possess inherent plasticity and resilience. The robust metabolic detoxification system likely protects these cells from oxidative stress and chemotherapeutic agents, potentially enabling their survival during treatment. This persistent, adaptive epithelial compartment could represent a cellular reservoir contributing to residual disease and treatment resistance in NMPR tumors. 

### 7. Refined Regulatory Network
Key Interactions:
  SOX2 -- KRT6A (transcriptional activation) - SOX2 is a well-established master regulator of basal cell fate in squamous epithelia and is co-enriched with KRT6A in the 'Basal cell' signature.
  SOX2 -- GPX2 (potential transcriptional regulation) - SOX2 and GPX2 are co-upregulated and co-enriched in the 'Basal cell' signature; SOX2 may regulate antioxidant genes in stem/progenitor cells.
  AKR1C1 -- AKR1C2 (functional cooperation) - These enzymes are co-expressed, share substrates (e.g., prostaglandins, steroids), and form the core of the 'Acinar cell' metabolic module.
  AKR1C2 -- AKR1C3 (functional cooperation) - Co-expressed and co-enriched in the 'Acinar cell' signature; they act in tandem to regulate intracellular levels of bioactive lipid mediators.
  GPX2 -- AKR1C family (functional synergy) - Both are upregulated and represent complementary cellular defense systems against oxidative and chemical stress, likely co-opted for therapy resistance.
  GPX2 -- KRT19 (co-expression / shared program) - These two genes are the shared components linking the 'Basal cell' and 'Luminal cell' signatures, indicating a common regulatory element or functional association in this hybrid state.

**Network Evidence:**
The network is centered on two core functional modules derived directly from the enrichment results. The first is a **SOX2-centered epithelial identity module**, evidenced by the 'Basal cell' signature containing SOX2, KRT6A, and GPX2. SOX2 is a known transcriptional hub for basal cell fate. The second is an **AKR1C metabolic detoxification module**, evidenced by the co-enrichment and high co-expression of AKR1C1, AKR1C2, and AKR1C3 in the 'Acinar cell' signature. These enzymes likely function as a cooperative complex to process a range of substrates. The gene GPX2 serves as a key connector, present in both basal and luminal signatures, and synergizes with the AKR1C module by handling peroxide byproducts of metabolic reactions, forming an integrated stress-defense apparatus. 

---

## Interpretation Result

### Cluster: 5

### 1. Overview
The enrichment analysis strongly indicates that the cell cluster is a macrophage population, specifically exhibiting features of alveolar macrophages and tumor-associated macrophages (TAMs) with an M2-like phenotype. The dominant biological signature is lipid metabolism and efferocytosis (supported by: Macrophage, Alveolar macrophage, Myeloid cell, M2 macrophage, Monocyte-derived macrophage, Tumor‐associated macrophage (TAM)). The high expression of genes like APOE, APOC1, MSR1, and MARCO points to a specialized functional state involved in cholesterol homeostasis and scavenging functions within the post-treatment, non-major pathologic response (NMPR) tumor microenvironment of LUSC. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor enrichment was provided in the top terms. However, based on the key marker genes, master regulators can be inferred. The coordinated high expression of APOE, APOC1, and MSR1 suggests activation of the LXR (Liver X Receptor) and PPARγ (Peroxisome Proliferator-Activated Receptor Gamma) signaling pathways, which are canonical drivers of lipid metabolism and alternative (M2-like) macrophage polarization. The expression of MARCO and VSIG4 further supports regulation by anti-inflammatory signals, potentially from the tumor microenvironment (e.g., IL-10, TGF-β). These inferred regulators drive the observed lipid-handling and immunosuppressive phenotype. 

### 3. Key Mechanisms
Two major interconnected mechanisms are identified: 1) **Lipid Metabolism and Transport**: Central to this cluster's identity is the robust expression of apolipoproteins (APOE, APOC1) and the scavenger receptor MSR1 (CD204), which are critical for cholesterol efflux, lipid uptake, and the formation of foam-cell-like macrophages (supported by: Macrophage, Alveolar macrophage, Myeloid cell). 2) **Scavenger Function and Immunomodulation**: High expression of pattern recognition receptors MARCO (scavenger receptor class A) and VSIG4 (V-set and Immunoglobulin domain containing 4) defines a state specialized in clearing apoptotic debris (efferocytosis) and suppressing adaptive immune responses, hallmarks of M2-like/TAMs (supported by: M2 macrophage, Tumor‐associated macrophage (TAM), Monocyte-derived macrophage). The presence of FCER1G and AIF1 (Iba1) reinforces general myeloid/macrophage lineage and activation. 

### 4. Crosstalk & Interactions
The mechanisms form a coherent, self-reinforcing network. Lipid uptake via MSR1 and other scavenger receptors provides ligands (e.g., oxysterols) for LXR nuclear receptors, which transcriptionally upregulate APOE and APOC1 to mediate cholesterol efflux. This lipid-handling program is intrinsically linked to an anti-inflammatory, pro-tolerogenic state. Simultaneously, efferocytosis mediated by receptors like MARCO and VSIG4 produces anti-inflammatory cytokines (e.g., TGF-β, IL-10), which further promote the M2-like polarization and lipid metabolic programs, creating a feedback loop that stabilizes the immunosuppressive TAM phenotype. 

### 5. Hypothesis
**What**: In post-treatment NMPR LUSC tumors, a resident alveolar macrophage-derived TAM population persists, characterized by a strong lipid metabolism and efferocytosis gene signature. **So What**: This specialized metabolic and scavenging phenotype may contribute to therapy resistance by (1) sustaining an immunosuppressive microenvironment that limits effective anti-tumor immunity, and (2) promoting tumor cell survival by resolving treatment-induced cell death and providing lipid-based metabolic support to the tumor. The persistence of this state post-chemotherapy/ICB suggests it is a stable, non-responsive niche. 

### 6. Narrative Draft
Functional enrichment analysis of a post-surgery cluster from NMPR LUSC patients treated with neoadjuvant camrelizumab and chemotherapy revealed a dominant macrophage identity. This population exhibits a transcriptomic profile consistent with alveolar macrophages and tumor-associated macrophages (TAMs) displaying an M2-like polarization state. The signature is defined by high expression of lipid-handling genes (APOE, APOC1, MSR1) and scavenger receptors (MARCO, VSIG4), implicating roles in cholesterol metabolism and efferocytosis. Within the context of a non-responding tumor, this suggests the persistence of a specialized TAM subset that may contribute to an immunosuppressive and metabolically supportive niche, potentially explaining the lack of major pathologic response despite combination therapy. 

### 7. Refined Regulatory Network
Key Interactions:
  MSR1 -- Cholesterol/Lipid Uptake (binding/activation) - MSR1 is a key scavenger receptor for modified lipoproteins, initiating lipid internalization. This is a core function of the cluster.
  LXR (inferred) -- APOE (activation) - APOE is a canonical target of LXR activation, central to the observed lipid efflux program.
  LXR (inferred) -- APOC1 (activation) - APOC1 is co-regulated with APOE by LXR, supporting the coordinated lipid metabolism signature.
  MARCO -- Efferocytosis (binding/activation) - MARCO mediates binding and phagocytosis of apoptotic cells, a key function linked to the M2-like/TAM phenotype.
  VSIG4 -- T-cell Suppression (inhibition) - VSIG4 is a known negative regulator of T-cell proliferation, linking the scavenger function to immunosuppression.
  APOE -- Cholesterol Efflux (activation) - APOE is essential for cholesterol transport out of cells, completing the lipid-handling cycle initiated by MSR1.

**Network Evidence:**
The network centers on a functional module for lipid homeostasis: MSR1 initiates uptake, while LXR-driven APOE/APOC1 mediate efflux. This forms a core metabolic cycle characteristic of foam-cell macrophages. A parallel, integrated module for immunomodulation involves MARCO and VSIG4, which are often co-expressed on regulatory macrophages. These receptors connect debris clearance (efferocytosis) directly to T-cell suppression. FCER1G (Fc receptor common gamma chain) and AIF1 serve as supporting markers of general myeloid lineage and activation, but are not central drivers of the specific phenotype. The co-expression of these genes defines a coherent TAM state with dual metabolic and immunosuppressive functions. 

---

## Interpretation Result

### Cluster: 6

### 1. Overview
The enrichment results overwhelmingly identify a cytotoxic and activated T/NK cell state. The top terms are all related to T cells (CD8+, CD4+, Cytotoxic T cell), natural killer cells, and lymphocytes, with the strongest statistical support for CD8+ T cell and NK cell identities. The gene list is dominated by canonical markers of cytotoxic lymphocytes (NKG7, GZMA), T cell receptor components (CD3E, TRAC, TRBC2), chemokines (CCL5, CCL4), and activation markers (CST7, IL32, CD2). This indicates the cluster represents a population of immune effector cells, likely tumor-infiltrating lymphocytes (TILs), with potent cytotoxic potential. 

### 2. Regulatory Drivers (TFs/Hubs)
While the provided enrichment list does not contain explicit transcription factor (TF) terms, the gene set allows inference of key regulators. The high expression of CCL5, GZMA, and NKG7 is classically associated with T-bet (TBX21) and Eomes (EOMES) activity in CD8+ T cells and NK cells. The co-expression of CCL4 and CCL5 also suggests potential NF-κB signaling. The gene CST7 (Cystatin F) is often associated with activated/effector T cells. Therefore, the master transcriptional drivers of this state are likely TBX21 and EOMES, which coordinate the cytotoxic effector program (GZMA, NKG7, PRF1) and chemokine expression (CCL5, CCL4) characteristic of effector T and NK cells. 

### 3. Key Mechanisms
Three major biological themes are evident: 1) **Cytotoxic Effector Function**: This is the core mechanism, driven by high expression of granzyme A (GZMA) and the cytolytic granule component NKG7 (supported by: Cytotoxic T cell, Effector CD8 T cell, Cytotoxic CD8+ T cell, Effector T(Teff) cell). 2) **T Cell Activation & Recognition**: Evidenced by the expression of T cell receptor (TCR) complex genes (CD3E, TRAC, TRBC2) and the co-stimulatory/adhesion molecule CD2 (supported by: T cell, CD8+ T cell, CD4+ T cell). 3) **Chemokine Signaling & Immune Recruitment**: High expression of the chemokines CCL5 (RANTES) and CCL4 (MIP-1β) indicates these cells can recruit other immune cells (supported by their presence in nearly all enriched cell type terms). The presence of IL32, a pro-inflammatory cytokine, further supports an active, inflammatory state. 

### 4. Crosstalk & Interactions
The pathways are intrinsically linked within the biology of an activated cytotoxic lymphocyte. TCR signaling (via CD3E, TRAC) initiates activation, leading to the upregulation of transcription factors like T-bet. T-bet then drives the expression of cytotoxic effector molecules (GZMA, NKG7) and chemokines (CCL5, CCL4). The secreted chemokines create a feed-forward loop, recruiting more T cells and myeloid cells (as hinted by the 'Myeloid cell' enrichment term linked to CCL4, CST7, NKG7, CD2), potentially amplifying the local immune response. The co-expression of markers shared with NK cells (NKG7, CST7) and γδ T cells suggests potential plasticity or a shared effector module across innate and adaptive cytotoxic lineages. 

### 5. Hypothesis
**What**: The analyzed cell cluster is a population of activated, cytotoxic CD8+ T cells and/or NK cells, characterized by a strong effector gene signature (GZMA, NKG7), chemokine production (CCL5, CCL4), and TCR expression. **So What**: In the context of post-surgery, non-major pathologic response (NMPR) LUSC tissue following neoadjuvant camrelizumab (anti-PD-1) + chemotherapy, the persistence of such a highly activated cytotoxic immune phenotype suggests that treatment did induce a robust T cell infiltration and activation. However, its presence in NMPR (rather than MPR/pCR) tissue implies these cells may be functionally impaired, excluded from the tumor parenchyma, or insufficient to overcome other immunosuppressive mechanisms, representing a 'failed' or 'ineffective' effector response. 

### 6. Narrative Draft
Functional enrichment analysis of the PostNMPR cluster revealed a definitive signature of cytotoxic lymphocyte activation. The cluster was most significantly annotated as CD8+ T cells and natural killer cells, with strong supporting terms for cytotoxic and effector T cell states (Fig. X). This was driven by high expression of canonical cytolytic mediators (NKG7, GZMA), T cell receptor components (CD3E, TRAC), and the T cell chemoattractants CCL5 and CCL4. The presence of this activated effector phenotype in surgical resection specimens from patients with non-major pathologic response indicates that neoadjuvant anti-PD-1 plus chemotherapy successfully primed and recruited cytotoxic lymphocytes to the tumor site. However, their failure to achieve major pathologic clearance suggests the existence of post-recruitment resistance mechanisms, such as T cell exhaustion, immunosuppressive cellular networks, or physical exclusion, which ultimately limited therapeutic efficacy. 

### 7. Refined Regulatory Network
Key Interactions:
  CD3E -- TRAC (complex_formation) - Core components of the T Cell Receptor (TCR) complex; essential for antigen recognition and initial T cell activation.
  TBX21 (inferred) -- GZMA (transcriptional_activation) - T-bet is a master regulator of cytotoxic effector function; GZMA is a direct target and key cytolytic molecule.
  TBX21 (inferred) -- CCL5 (transcriptional_activation) - T-bet drives expression of CCL5, linking T cell activation to chemokine-mediated recruitment of other immune cells.
  CCL5 -- CCR5 (inferred) (binds) - CCL5 signals through CCR5 on T cells and myeloid cells, establishing a chemotactic feedback loop for immune cell recruitment.
  NKG7 -- GZMA (co-localization) - NKG7 is a component of cytolytic granules; its expression is co-regulated with granzymes and is critical for their release.
  CD2 -- CD58 (inferred) (adhesion) - CD2 is a co-stimulatory/adhesion molecule; interaction with CD58 on APCs enhances T cell activation and immune synapse stability.

**Network Evidence:**
The network centers on two core functional modules: 1) The **TCR Activation Module** (CD3E, TRAC, CD2), which initiates the cellular response. 2) The **Cytotoxic Effector Module** (NKG7, GZMA), which executes the killing function, likely driven by the inferred hub transcription factor TBX21. These modules are linked by the **Chemokine Signaling Node** (CCL5), which is both an output of activation and an input for further immune recruitment. The protein product of NKG7 is known to form part of the granule membrane, facilitating the release of GZMA, representing a direct protein-level functional partnership within the cytotoxic machinery. 

---

## Interpretation Result

### Cluster: 7

### 1. Overview
The enrichment analysis strongly identifies a myeloid cell population, specifically macrophages and dendritic cell subsets, with a pronounced inflammatory and immunosuppressive signature. The top enriched terms are predominantly cell type annotations (e.g., Macrophage, cDC2b, Myeloid cell) rather than canonical pathways, indicating the analysis is defining a cellular identity. The core gene set (FGL2, LYZ, FCN1, MNDA, VCAN, TYROBP, FCER1G, IL1B, AIF1, BCL2A1) is characteristic of innate immune myeloid cells. The high expression of IL1B, FCN1, and VCAN points to an active, pro-inflammatory state, while markers like FGL2 and BCL2A1 suggest concurrent immunosuppressive and survival programming. This profile is consistent with a tumor-associated myeloid state observed in the post-treatment, non-major pathologic response (NMPR) setting of LUSC. 

### 2. Regulatory Drivers (TFs/Hubs)
While no specific transcription factors (TFs) are listed in the provided enrichment results, the gene set implicates key myeloid regulators. The hub gene TYROBP (DAP12) is a critical signaling adaptor for activating receptors on myeloid cells (e.g., TREM2, SIRP1). Its co-expression with FCER1G (FcRγ) suggests signaling through immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors is a central driver. The high expression of IL1B indicates potential activity of the NF-κB and NLRP3 inflammasome pathways as downstream transcriptional regulators of the inflammatory response. The presence of BCL2A1, an NF-κB target gene, further supports NF-κB activation. Thus, the master regulatory module is inferred to be ITAM (TYROBP/FCER1G) → NF-κB/Inflammasome → Pro-inflammatory & Survival Gene Output (IL1B, BCL2A1). 

### 3. Key Mechanisms
Three intertwined mechanistic themes are identified: 1) **Myeloid Cell Identity & Recruitment**: The core gene set defines a mixed macrophage/dendritic cell/monocyte state (supported by: Macrophage, cDC2b, Myeloid cell, Classical monocyte). VCAN (versican) and FCN1 (ficolin-1) are involved in myeloid cell adhesion and recruitment. 2) **Pro-inflammatory Signaling**: A strong interleukin-1 beta (IL1B) driven inflammatory response is evident (supported by its high log2FC and enrichment in terms like M1 macrophage and Paneth cell, which are IL1B-expressing cells). 3) **Immunomodulation & Survival**: The expression of FGL2 (a fibrinogen-like protein 2 immunosuppressor) and the anti-apoptotic gene BCL2A1 indicates a regulatory, potentially pro-tumorigenic, phenotype (supported by enrichment in Paneth cell and MDSC-related terms). The co-presence of IL1B and FGL2 suggests a paradoxically 'activated but suppressive' state. 

### 4. Crosstalk & Interactions
The network is centered on a core module of myeloid activation receptors (signaling through TYROBP/FCER1G) that can trigger both the IL1B inflammasome pathway and survival pathways via BCL2A1. The product of one pathway can feed into another; for example, IL1B signaling can further activate NF-κB, which transcriptionally upregulates BCL2A1 and potentially VCAN. Furthermore, FGL2 can act in a paracrine manner to suppress T-cell function, creating an immunosuppressive feedback loop that may negate the pro-inflammatory alarm signal from IL1B. The shared genes across dendritic cell (LYZ, TYROBP, FCER1G, AIF1) and macrophage annotations indicate a continuum or plasticity between these myeloid lineages in this context. 

### 5. Hypothesis
**What**: The post-treatment NMPR LUSC microenvironment harbors a dominant myeloid cell state co-expressing markers of classical monocytes (FCN1, VCAN), inflammatory macrophages (IL1B, AIF1), and immunosuppressive effectors (FGL2, BCL2A1). **So What**: This specific myeloid phenotype, driven by ITAM (TYROBP/FCER1G) and NF-κB signaling, represents a treatment-resistant niche. It simultaneously sustains a smoldering inflammation (via IL1B) that may support tumor cell survival and tissue remodeling, while actively suppressing adaptive anti-tumor immunity (via FGL2). This dual mechanism could contribute to the lack of major pathologic response (NMPR) following neoadjuvant chemo-immunotherapy. 

### 6. Narrative Draft
Single-cell analysis of post-surgical LUSC samples from patients with non-major pathologic response (NMPR) to neoadjuvant camrelizumab plus chemotherapy revealed a dominant myeloid cell cluster. This population exhibited a hybrid identity, with strong enrichment for macrophage, conventional dendritic cell 2b (cDC2b), and monocyte annotations. The marker gene profile was characterized by high expression of canonical myeloid markers (LYZ, AIF1, MNDA), adhesion molecules (VCAN), and the pattern recognition receptor FCN1. Critically, this state co-expressed the potent pro-inflammatory cytokine IL1B alongside the immunosuppressive factor FGL2 and the anti-apoptotic protein BCL2A1. The consistent presence of the signaling adaptors TYROBP and FCER1G suggests activation through ITAM-coupled receptors. We propose this myeloid subset represents an inflammation-polarized, yet immunosuppressive, tumor-associated phenotype that may undermine effective anti-tumor immunity and contribute to treatment resistance in NMPR patients. 

### 7. Refined Regulatory Network
Key Interactions:
  TYROBP -- SYK (activation) - TYROBP (DAP12) is an ITAM-bearing adaptor that recruits and activates SYK kinase upon receptor engagement, a central signal in myeloid cell activation.
  FCER1G -- SYK (activation) - FCER1G (FcRγ) is another ITAM adaptor that complexes with TYROBP or alone to activate SYK, amplifying the activation signal.
  SYK -- NFKB1 (activation) - SYK kinase activates the NF-κB pathway, a master regulator of inflammatory and survival genes, including IL1B and BCL2A1.
  NFKB1 -- IL1B (activation) - IL1B is a canonical NF-κB target gene; its high expression is direct evidence of this pathway's activity.
  NFKB1 -- BCL2A1 (activation) - BCL2A1 is a known NF-κB target gene, linking the activation signal to a pro-survival outcome.
  IL1B -- IL1R1 (binding) - Secreted IL1B can act in an autocrine/paracrine manner by binding to IL-1 receptor, creating a positive feedback loop that sustains NF-κB activity and inflammation.
  FGL2 -- T-cell Function (inhibition) - FGL2 is a secreted immunosuppressive protein that binds to FcγRIIB on T cells and dendritic cells, inhibiting their activation and function.

**Network Evidence:**
The refined network centers on the **ITAM-SYK-NF-κB signaling module**, which is strongly supported by the co-expression of the adaptor proteins TYROBP and FCER1G with the downstream effector genes IL1B and BCL2A1. This module is a classic pathway for innate immune cell activation. The inclusion of **FGL2** as a separate, key output creates a **bifunctional signaling module**: one arm (NF-κB→IL1B) drives inflammation and potentially tissue repair/pro-tumorigenic signaling, while the other (secretion of FGL2) directly suppresses adaptive immunity. This network architecture provides a mechanistic basis for the observed 'activated but suppressive' myeloid phenotype linked to treatment resistance. 

---

## Interpretation Result

### Cluster: 8

### 1. Overview
The enrichment analysis of the PostNMPR LUSC cluster reveals a dominant vascular and stromal phenotype, with strong signatures of endothelial cells (Vascular cell, Vascular endothelial cell, Pan-endothelial cell) and fibroblasts (Fibroblast, Cancer-associated fibroblast). A notable proliferative signature (MKI67+ progenitor cell) is also present. The gene expression profile is driven by highly upregulated markers of vascular integrity (VWF, PECAM1, CALCRL), stromal communication (IGFBP7, SPARCL1, MGP), and a proliferative marker (GNG11). This suggests a tumor microenvironment state in non-responding patients post-treatment that is enriched for vascular and stromal remodeling cells, potentially associated with treatment resistance. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor enrichments were provided in the top terms. However, key hub genes from the marker list can be inferred as functional drivers. VWF and PECAM1 (CD31) are master regulators of endothelial cell identity and vasculature. CALCRL (Calcitonin receptor-like) is a key component of the adrenomedullin receptor, a potent regulator of vascular biology and potential tumor-stroma crosstalk. The co-upregulation of these genes suggests a concerted program driving vascular phenotypes. The presence of the 'MKI67+ progenitor cell' term, anchored by GNG11 (a signaling protein often associated with proliferative states), hints at a proliferative sub-component, though the specific upstream transcriptional regulator (e.g., E2F family) is not identified in this enrichment set. 

### 3. Key Mechanisms
1. **Vascular Remodeling and Angiogenesis:** This is the most prominent theme, supported by the enrichment of Vascular cell, Vascular endothelial cell, and Pan-endothelial cell terms, driven by the strong upregulation of canonical endothelial markers VWF and PECAM1, and the endothelial receptor CALCRL. 2. **Stromal Activation and Fibroblast Phenotype:** Supported by the Fibroblast and Cancer-associated fibroblast (CAF) terms, driven by genes like IGFBP7, SPARCL1, and CAV1. These genes are involved in extracellular matrix (ECM) organization, cell adhesion, and stromal signaling. 3. **Proliferative Capacity:** Supported by the MKI67+ progenitor cell term, though the classic marker MKI67 itself is not in the top gene list. The term's association with genes like GNG11 (a G-protein subunit involved in signaling) and vascular genes (VWF, PECAM1) may indicate a specific proliferative vascular progenitor or activated endothelial state. 

### 4. Crosstalk & Interactions
A core network of crosstalk is evident between the vascular and stromal compartments. The gene IGFBP7 appears in both fibroblast/CAF and vascular-related terms (Fibrocartilage chondrocyte, Cancer-associated fibroblast), positioning it as a potential communication node. IGFBP7 can be secreted by fibroblasts and endothelial cells, influencing angiogenesis and cell growth. Furthermore, VWF (a primary vascular gene) also appears in the Cancer-associated fibroblast term, suggesting possible endothelial-mesenchymal transition (EndMT) or strong paracrine signaling between CAFs and endothelium. CALCRL and CAV1 (caveolin-1), which form the 'Pan-endothelial cell' term, are critical for endothelial signaling and mechanotransduction, potentially integrating signals from the remodeled stroma. 

### 5. Hypothesis
**What:** In LUSC patients with a non-major pathologic response (NMPR) after neoadjuvant camrelizumab + chemotherapy, the post-surgery tumor microenvironment is enriched for a cellular state co-expressing markers of active vasculature (VWF+, PECAM1+, CALCRL+), activated stroma (IGFBP7+, SPARCL1+), and proliferation (GNG11+). **So What:** This specific vascular-stromal phenotype may represent a microenvironmental adaptation that persists or emerges post-treatment, contributing to resistance. The activated, potentially proliferative vasculature could sustain a tumor-permissive niche, while the associated CAF-like signature may promote immune exclusion or tissue remodeling that limits therapy efficacy. This state could be a target for adjuvant therapies combining anti-angiogenics or stromal modulators with ICB. 

### 6. Narrative Draft
Functional enrichment analysis of a post-treatment, non-responding (PostNMPR) LUSC cluster revealed a dominant signature of vascular and stromal remodeling. We observed significant enrichment of terms associated with vascular endothelial cells (e.g., Vascular endothelial cell, Pan-endothelial cell) and fibroblasts (e.g., Fibroblast, Cancer-associated fibroblast), alongside a proliferative progenitor-like signature (MKI67+ progenitor cell). This phenotype is driven by the marked upregulation of canonical endothelial markers VWF and PECAM1 (CD31), the adrenomedullin receptor component CALCRL, and stromal factors IGFBP7 and SPARCL1. The co-expression of these markers suggests a tumor microenvironment state in non-responders characterized by an active, potentially proliferative vasculature intertwined with an activated fibroblast compartment. This vascular-stromal axis may represent a key microenvironmental feature of residual disease post-ICB/chemotherapy, possibly contributing to treatment resistance through the maintenance of a supportive niche and potential modulation of immune infiltration. 

### 7. Refined Regulatory Network
Key Interactions:
  VWF -- PECAM1 (co-expression/complex) - Core endothelial cell adhesion and signaling complex (Weibel-Palade body component and surface receptor); their joint upregulation defines the vascular phenotype.
  VWF -- CALCRL (regulatory/co-expression) - CALCRL is a receptor for vasoactive peptides (e.g., adrenomedullin) that regulate endothelial function and VWF release; they are co-upregulated in the pan-endothelial signature.
  VWF -- IGFBP7 (signaling/co-regulation) - IGFBP7 is a stromal factor appearing in CAF and vascular-related terms; it can influence endothelial biology and is co-mentioned with VWF in the 'Cancer-associated fibroblast' term, suggesting a functional module in tumor-stroma-vessel crosstalk.
  CALCRL -- CAV1 (complex/co-localization) - Both are markers in the 'Pan-endothelial cell' term; CAV1 (caveolin-1) forms caveolae that compartmentalize signaling molecules like GPCRs (e.g., CALCRL), crucial for endothelial signaling.
  IGFBP7 -- SPARCL1 (co-expression/functional synergy) - Co-upregulated genes central to the Fibroblast and Fibrocartilage chondrocyte terms; both are matricellular proteins involved in ECM organization and cell-matrix adhesion, representing a core stromal module.
  CALCRL -- GNG11 (signaling) - GNG11 is a G-protein gamma subunit; CALCRL is a GPCR. Their co-upregulation (GNG11 in the proliferative term, CALCRL in vascular terms) suggests active G-protein coupled receptor signaling potentially linking vascular sensing to cellular responses.

**Network Evidence:**
The refined network highlights two primary functional modules: 1) A **Vascular Adhesion/Signaling Module** comprising VWF, PECAM1, CALCRL, and CAV1. VWF and PECAM1 form a core endothelial adhesive apparatus. CALCRL (a GPCR) and its potential spatial organizer CAV1 represent a key signaling hub for vascular permeability and angiogenesis. 2) A **Stromal Matricellular Module** centered on IGFBP7 and SPARCL1, which are co-expressed in fibroblast signatures and function in ECM remodeling. The connection between these modules is evidenced by IGFBP7's association with both stromal and vascular terms, and the potential signaling link from the vascular GPCR (CALCRL) via G-proteins (GNG11). This network structure supports the interpretation of an integrated vascular-stromal functional unit in the PostNMPR microenvironment. 

---

## Interpretation Result

### Cluster: 9

### 1. Overview
The enrichment analysis of a post-treatment, non-major pathologic response (NMPR) LUSC sample reveals a dominant signature of secretory and epithelial cell identity. The top enriched terms are 'Secretory cell' and 'Epithelial cell' (supported by: Secretory cell, Epithelial cell). The key upregulated genes (SFTPA1, SFTPD, SLPI, PIGR, SLC34A2, MUC1) are classic markers of lung epithelial differentiation, specifically associated with alveolar type II cells (SFTPA1, SFTPD), mucosal immunity and secretory function (PIGR, SLPI), and epithelial barrier integrity (MUC1, SLC34A2). This suggests a program of epithelial restoration and innate immune defense is active in this post-treatment, residual disease context. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor (TF) enrichment was provided in the top terms. However, based on standard biological knowledge of the key marker genes, potential inferred master regulators include: 1) **NKX2-1 (TTF-1)**, a master TF for lung epithelial cell differentiation and a known regulator of SFTPA1, SFTPD, and SLC34A2. Its activity would drive the alveolar epithelial cell state. 2) **STAT3/6** and **NF-κB**, which are activated by cytokine signaling (e.g., IL-4, IL-13) and can drive the expression of secretory immune mediators like PIGR and SLPI. The co-expression of these gene modules suggests coordinated activity of lineage-defining (NKX2-1) and inflammatory (STAT/NF-κB) transcriptional programs in these epithelial cells. 

### 3. Key Mechanisms
Two interconnected biological mechanisms are identified: 1) **Alveolar Epithelial Homeostasis and Surfactant Production**: Upregulation of SFTPA1 and SFTPD (supported by gene list) indicates active surfactant protein synthesis, a core function of alveolar type II cells critical for lung function and innate immune defense in the alveoli. 2) **Mucosal Barrier Defense and Secretory Immune Response**: Upregulation of PIGR (polymeric immunoglobulin receptor), SLPI (secretory leukocyte protease inhibitor), and MUC1 (mucin 1) (supported by gene list) points to enhanced mucosal immunity. PIGR mediates IgA transcytosis, SLPI protects against proteolytic damage and has antimicrobial properties, and MUC1 is a barrier-forming glycoprotein. SLC34A2, involved in phosphate transport, is also linked to surfactant metabolism and alveolar function. 

### 4. Crosstalk & Interactions
The crosstalk centers on the epithelial cell as a unified effector. The **NKX2-1-driven alveolar differentiation program** (producing SFTPA1/D) and the **inflammatory cytokine-driven secretory program** (producing PIGR, SLPI) likely converge. For instance, surfactant proteins (SFTPA1/D) themselves have immunomodulatory roles, potentially influencing the local cytokine milieu that then further amplifies PIGR/SLPI expression via STAT/NF-κB. MUC1 can also modulate inflammatory signaling. This creates a feed-forward loop where epithelial repair and innate immune activation are co-regulated, reinforcing a barrier-protective state in the tissue. 

### 5. Hypothesis
**What**: The post-treatment NMPR LUSC sample exhibits a strong gene expression signature of alveolar epithelial differentiation and mucosal secretory immune function. **So What**: This signature likely represents a state of **therapy-induced epithelial resilience and active tissue repair**. In the context of residual disease after neoadjuvant chemo-immunotherapy (Camrelizumab), this may indicate a tumor microenvironment where surviving epithelial/tumor cells have adopted a differentiated, barrier-protective phenotype that could contribute to resistance by: (1) enhancing physical and immunological barriers against immune cell infiltration or cytotoxicity, (2) secreting anti-inflammatory factors (e.g., SLPI) that dampen local immune responses, and (3) maintaining alveolar-like homeostasis that promotes cell survival. This program may be a hallmark of epithelial persistence in non-responders. 

### 6. Narrative Draft
Analysis of a post-surgical sample from a non-major pathologic responder (NMPR) with LUSC revealed a dominant transcriptional signature of secretory and epithelial cell identity. Key marker genes included surfactant proteins SFTPA1 and SFTPD, indicative of alveolar type II cell differentiation, alongside mucosal defense molecules PIGR, SLPI, and MUC1. This co-expression pattern suggests a concerted biological program of epithelial homeostasis and innate immune barrier function is active in the residual tissue following neoadjuvant camrelizumab and chemotherapy. We hypothesize that this differentiated, secretory phenotype may represent a state of adaptive resilience, where epithelial cells fortify barrier defenses and secrete immunomodulatory factors, potentially contributing to a microenvironment that limits therapy efficacy and facilitates tumor cell persistence in non-responding patients. 

### 7. Refined Regulatory Network
Key Interactions:
  NKX2-1 (TTF-1) -- SFTPA1 (activation) - Master regulator of lung epithelial cell fate; directly activates surfactant protein genes. Key driver of the alveolar module.
  NKX2-1 (TTF-1) -- SFTPD (activation) - Master regulator of lung epithelial cell fate; directly activates surfactant protein genes. Key driver of the alveolar module.
  NKX2-1 (TTF-1) -- SLC34A2 (activation) - Known transcriptional target of NKX2-1 in lung epithelium, linking differentiation to ion transport.
  STAT3/NF-κB -- PIGR (activation) - PIGR expression is induced by inflammatory cytokines (e.g., IL-4, IL-13, TNF) via STAT and NF-κB pathways. Core to the secretory immune module.
  STAT3/NF-κB -- SLPI (activation) - SLPI is an acute phase protein whose expression is upregulated by inflammatory signals, including those activating NF-κB.
  SFTPA1 -- Immune Modulation (regulation) - Surfactant protein A can modulate macrophage and lymphocyte activity, providing a functional link between the alveolar and immune modules.
  SLPI -- Protease Inhibition / NF-κB (inhibition) - SLPI inhibits neutrophil elastase and can also inhibit NF-κB signaling, creating a potential negative feedback loop within the inflammatory secretory program.

**Network Evidence:**
The refined network is centered on two functional modules connected through the epithelial cell state. The **Alveolar Differentiation Module** is defined by the co-regulation of SFTPA1, SFTPD, and SLC34A2 by the hub transcription factor NKX2-1, representing a core program for lung-specific epithelial function. The **Secretory Immune Module** is defined by the co-expression of PIGR and SLPI, which are both responsive to inflammatory cytokine signaling (STAT/NF-κB hubs) and function in concert at mucosal surfaces—PIGR in antibody transport and SLPI in protease inhibition and antimicrobial defense. The connection between these modules is evidenced by the shared epithelial context and the known immunomodulatory roles of surfactant proteins (e.g., SFTPA1), suggesting an integrated response where differentiation and innate immunity are coordinately regulated. 

---

## Interpretation Result

### Cluster: 10

### 1. Overview
The enrichment analysis identifies a dominant epithelial cell identity program in this post-treatment, non-major pathologic response (NMPR) LUSC cluster. The top terms point to a secretory, luminal, and cancer cell phenotype, driven by a core set of epithelial marker genes (KRT7, KRT18, MUC1, CEACAM6, WFDC2, NAPSA, SLC34A2, SFTPB). This suggests the persistence of a differentiated, potentially therapy-resistant epithelial cell state after neoadjuvant camrelizumab + chemotherapy. 

### 2. Regulatory Drivers (TFs/Hubs)
While the provided enrichment list does not contain explicit transcription factor (TF) terms, the core gene set allows inference of potential upstream regulators. The strong co-expression of KRT7, KRT18, MUC1, and CEACAM6 is characteristic of luminal/epithelial differentiation programs often governed by TFs like GATA6, FOXA1, and ELF3 in lung and other epithelial tissues. The secretory module (SLC34A2, SFTPB, WFDC2) may be influenced by NKX2-1 (TTF-1), a master regulator of lung alveolar cell differentiation and surfactant production. The persistence of this program in NMPR suggests these TFs may be maintaining a differentiated, non-proliferative state that confers resistance to immune-chemo therapy. 

### 3. Key Mechanisms
Two intertwined biological themes are identified: 1) **Epithelial/Cancer Cell Identity Maintenance (supported by: Cancer cell, Epithelial cell, Paget cell, Luminal cell, Ductal cell)**: This is defined by cytokeratins (KRT7, KRT18) and membrane proteins (MUC1, CEACAM6) that provide structural integrity and mediate cell-cell adhesion and signaling. 2) **Secretory/Luminal Function (supported by: Secretory cell, Epithelial progenitor cell)**: This involves genes for surfactant production (SFTPB), solute transport (SLC34A2), and protease inhibition (WFDC2), indicating specialized metabolic and secretory activity. The 'Epithelial progenitor cell' term hints at a capacity for self-renewal or plasticity within this differentiated state. 

### 4. Crosstalk & Interactions
The mechanisms are highly integrated. The epithelial identity program (cytokeratins, MUC1) establishes the cellular context. Within this context, the secretory function module (SFTPB, SLC34A2) executes tissue-specific physiology. CEACAM6 and MUC1 are key crosstalk nodes; they are part of the epithelial identity signature but also function in cell signaling (CEACAM6 in immune modulation and survival, MUC1 in barrier function and oncogenic signaling), potentially linking the cell's structural state to its interaction with the microenvironment and therapy response. The co-enrichment of 'Cancer cell' and 'Secretory cell' terms suggests this is a malignant, yet functionally differentiated, epithelial state. 

### 5. Hypothesis
**What**: The post-treatment NMPR LUSC cluster is enriched for a luminal secretory epithelial cell state defined by KRT7/KRT18/MUC1/CEACAM6 and surfactant-related genes. **So What**: This specific differentiated epithelial program may represent a non-proliferative, therapy-resistant cell state that survived neoadjuvant combo therapy. The secretory phenotype (e.g., SFTPB, WFDC2) could alter the local tumor microenvironment, while surface molecules like MUC1 and CEACAM6 may directly impede immune cell recognition or function, contributing to the observed lack of major pathologic response. 

### 6. Narrative Draft
In post-surgical samples from LUSC patients with a non-major pathologic response (NMPR) to neoadjuvant camrelizumab and chemotherapy, we identified a cell cluster exhibiting a strong epithelial and secretory signature. This state is characterized by high expression of canonical epithelial markers KRT7, KRT18, and MUC1, alongside genes associated with specialized secretory function such as SFTPB and SLC34A2. The enrichment of terms like 'Secretory cell', 'Cancer cell', and 'Luminal cell' indicates the persistence of a differentiated malignant epithelial program post-treatment. The presence of immune-modulatory surface proteins like CEACAM6 and MUC1 within this signature suggests this cell state may not only be structurally resistant but also actively engaged in suppressing anti-tumor immunity. Thus, this luminal secretory phenotype likely represents a resilient, functionally adapted tumor cell population that evaded therapy-induced elimination. 

### 7. Refined Regulatory Network
Key Interactions:
  KRT18 -- KRT7 (co-expression/structural complex) - Core components of the intermediate filament cytoskeleton defining epithelial/luminal cell identity; consistently co-upregulated in the gene list and central to multiple enriched terms (Epithelial cell, Cancer cell, Luminal cell).
  MUC1 -- CEACAM6 (co-expression/functional synergy) - Both are transmembrane glycoproteins upregulated in epithelial/cancer cells, involved in cell adhesion, signaling, and immune modulation; co-occur in 'Cancer cell' and 'Paget cell' terms, suggesting a shared role in the resistant phenotype.
  SFTPB -- SLC34A2 (co-expression/functional module) - Core genes defining the 'Secretory cell' term; SFTPB is a surfactant protein and SLC34A2 is a phosphate transporter, together representing key functional outputs of a differentiated lung secretory cell.
  WFDC2 -- Protease Targets (binding/activation) - WFDC2 is a protease inhibitor; its inclusion in 'Secretory cell' and 'Ductal cell' terms suggests its activity is a key part of the secretory module, potentially protecting the epithelium or remodeling the extracellular matrix.

**Network Evidence:**
The network analysis reveals a core epithelial-cytoskeletal module (KRT18-KRT7) and a secretory functional module (SFTPB-SLC34A2). These modules are bridged by multifunctional signaling molecules MUC1 and CEACAM6, which are integral to the 'Cancer cell' and 'Epithelial cell' identities. This structure suggests a cohesive cellular program where the maintenance of epithelial integrity (via cytokeratins) is coupled with specialized secretory function and is decorated with surface molecules capable of microenvironmental interaction. The presence of WFDC2, a protease inhibitor, within this network further supports an active role in shaping the pericellular environment. This integrated module represents a stable, functional state distinct from proliferative or stem-like programs. 

---

## Interpretation Result

### Cluster: 11

### 1. Overview
The enrichment results overwhelmingly identify a mesenchymal, contractile stromal cell population. The top terms are all related to fibroblast, myofibroblast, and smooth muscle phenotypes (Myofibroblast, Fibroblast, Smooth muscle cell, Cancer-associated fibroblast). The core gene set (ACTA2, TAGLN, MYL9, COL1A2, DCN, MYLK, TPM2, CALD1) defines a cell state characterized by extracellular matrix (ECM) production and cytoskeletal contraction. This is a definitive signature of activated cancer-associated fibroblasts (CAFs), specifically the myofibroblastic (mCAF) or contractile subtype, within the post-treatment, non-major pathologic response (NMPR) tumor microenvironment of LUSC. 

### 2. Regulatory Drivers (TFs/Hubs)
While no explicit transcription factor (TF) enrichment was provided in the top terms, the core gene set points to key regulators of mesenchymal and smooth muscle differentiation. The universal expression of ACTA2 (alpha-smooth muscle actin) is a hallmark downstream target of the TGF-β signaling pathway and its effectors (e.g., SMADs). MYOCD (Myocardin) and SRF (Serum Response Factor) are master regulators of smooth muscle and fibroblast contractile gene programs, directly activating genes like ACTA2, TAGLN, MYL9, and MYLK. The enrichment of 'Myofibroblast' and 'Smooth muscle cell' phenotypes is the functional readout of this SRF/MYOCD-driven transcriptional program. Furthermore, the high expression of structural genes like TPM2 and CALD1 suggests stabilization of the actin cytoskeleton, a process coordinated by these TFs. 

### 3. Key Mechanisms
Two major, intertwined biological themes are identified:
1.  **ECM Remodeling and Fibrosis:** Supported by high expression of core structural collagens (COL1A2) and ECM organizers (DCN, MFAP4, IGFBP7). This gene module is central to the 'Fibroblast', 'Stromal cell', and 'Cancer-associated fibroblast' terms and drives tumor desmoplasia, creating a physical barrier to therapy.
2.  **Cytoskeletal Contraction and Motility:** Supported by the contractile apparatus genes (ACTA2, TAGLN, MYL9, MYLK, TPM2, CALD1). This module defines the 'Myofibroblast', 'Smooth muscle cell', and 'Pericyte' terms. It confers contractile force, influencing tissue stiffness, vascular perfusion, and potentially immune cell trafficking.
The co-expression of both modules is the defining feature of activated, myofibroblastic CAFs. 

### 4. Crosstalk & Interactions
The two key mechanisms are functionally linked in a feed-forward loop. The TGF-β pathway (inferred from the phenotype) activates the contractile program via SRF/MYOCD, leading to ACTA2 expression and cytoskeletal tension. This tension, in turn, promotes further ECM production and remodeling. Furthermore, the 'Pericyte' and 'Vascular smooth muscle cell' associations suggest these CAFs may interact with and stabilize tumor vasculature, influencing drug delivery. The shared genes (e.g., ACTA2, TAGLN) across 'Smooth muscle', 'Perivascular', and 'Myofibroblast' terms highlight a phenotypic continuum and potential functional crosstalk between stromal compartments in shaping the post-treatment niche. 

### 5. Hypothesis
**What:** In post-surgical LUSC samples from patients with a non-major pathologic response (NMPR) to neoadjuvant camrelizumab + chemotherapy, we identify a dominant stromal cell cluster defined by a co-expression program of ECM production and cytoskeletal contraction, consistent with an activated myofibroblastic CAF (mCAF) state.
**So What:** The persistence of this activated mCAF population post-treatment suggests it may contribute to therapeutic resistance. The mCAFs could promote resistance by (1) generating a fibrotic, immunosuppressive ECM barrier that impedes drug penetration and immune cell infiltration, and (2) through contractile force, altering tissue mechanics and vascular function to create a survival niche for residual tumor cells. This stromal signature may be a biomarker for and a potential therapeutic target in treatment-resistant LUSC. 

### 6. Narrative Draft
In the post-treatment tumor microenvironment of non-responding (NMPR) LUSC patients, we identified a predominant stromal cell population exhibiting a canonical myofibroblastic signature. This state is defined by the concurrent high expression of extracellular matrix genes (COL1A2, DCN) and a suite of smooth muscle contractile proteins (ACTA2, TAGLN, MYL9, MYLK). Functional enrichment analysis robustly annotated this cluster as Myofibroblast, Fibroblast, and Smooth muscle cell, with strong associations to Cancer-associated fibroblast and Pericyte phenotypes. The persistence of this activated, contractile CAF subset post-chemotherapy and immunotherapy suggests a potential role in therapeutic resistance. These cells likely contribute to a fibrotic and mechanically rigid niche that may physically constrain immune cell mobility and drug efficacy, offering a stromal-centric explanation for the observed lack of major pathologic response. 

### 7. Refined Regulatory Network
Key Interactions:
  TGFB1 (inferred ligand) -- ACTA2 (activation) - TGF-β is the canonical upstream signal inducing alpha-smooth muscle actin (ACTA2) expression and myofibroblast differentiation; ACTA2 is the central hub of the provided gene set.
  SRF/MYOCD (inferred complex) -- ACTA2 (activation) - SRF/MYOCD is the master transcriptional complex driving contractile gene expression; ACTA2 is a direct target.
  SRF/MYOCD (inferred complex) -- TAGLN (activation) - TAGLN (SM22α) is a classic smooth muscle and myofibroblast marker directly regulated by SRF/MYOCD.
  SRF/MYOCD (inferred complex) -- MYL9 (activation) - MYL9 (Myosin Light Chain 9) is a key component of the contractile apparatus and a known target of this pathway.
  ACTA2 -- TPM2 (binding/complex) - TPM2 (Tropomyosin 2) binds to and stabilizes actin filaments (containing ACTA2), forming the core cytoskeletal structure.
  ACTA2 -- CALD1 (binding/regulation) - CALD1 (Caldesmon) binds actin (ACTA2) and myosin to regulate contractility, linking the structural and contractile modules.
  COL1A2 -- DCN (binding) - DCN (Decorin) directly binds to and organizes collagen fibrils (containing COL1A2), representing a core ECM remodeling module.
  MYLK -- MYL9 (activation/phosphorylation) - MYLK (Myosin Light Chain Kinase) phosphorylates MYL9 to activate actomyosin contractility, a direct mechanistic link within the contractile module.

**Network Evidence:**
The provided gene set forms a coherent functional module centered on the ACTA2 protein. The network reveals two tightly connected sub-modules: 1) A **cytoskeletal-contractile complex** comprising ACTA2, TPM2, CALD1, MYL9, and its regulator MYLK. This complex executes physical force generation. 2) An **ECM structural complex** centered on COL1A2 and its interacting partner DCN, responsible for matrix deposition. The connection between these modules is established biologically through common upstream signaling (e.g., TGF-β/SRF) and mechanically, as actin contractility (Module 1) drives the assembly and remodeling of the ECM (Module 2). The presence of MFAP4 and IGFBP7 further supports the ECM niche specialization of this stromal population. 

---

## Interpretation Result

### Cluster: 12

### 1. Overview
The enrichment analysis of a post-treatment, non-major pathologic response (NMPR) LUSC sample reveals a dominant signature of basal epithelial cell identity (Basal cell, Luminal cell, Epithelial cell). This is characterized by the strong upregulation of a core set of keratin genes (KRT6A, KRT17, KRT19) and epithelial stress/barrier genes (CSTA, SFN, GPX2). The results indicate a cellular state centered on epithelial structural integrity, differentiation, and oxidative stress response, rather than overt proliferation or immune activation. 

### 2. Regulatory Drivers (TFs/Hubs)
While no specific transcription factors (TFs) were provided in the top enriched terms, the key marker genes are known targets of master regulators of squamous epithelial differentiation. The hub gene KRT17 is a classic target of the p63 transcription factor, a master regulator of basal cell identity and stratification in squamous epithelia. The co-expression of KRT6A and KRT17 is a hallmark of p63-driven programs. Furthermore, SFN (stratifin/14-3-3σ) is a p53-regulated gene involved in cell cycle control and epithelial differentiation. Thus, the observed gene module is likely driven by the activity of p63 and p53, reinforcing a basal-like, potentially growth-arrested or differentiated epithelial state. 

### 3. Key Mechanisms
Two interconnected biological themes are identified: 1) **Squamous Epithelial Differentiation and Structural Integrity**: Supported by the enrichment of 'Basal cell', 'Luminal cell', and 'Epithelial cell' terms, driven by keratins (KRT6A, KRT17, KRT19) which form the cytoskeleton, and CSTA (cystatin A), a protease inhibitor crucial for epithelial barrier function. 2) **Epithelial Stress and Detoxification Response**: Supported by the high expression of SFN (a cell cycle regulator and stress sensor) and GPX2 (glutathione peroxidase 2), a key antioxidant enzyme protecting epithelial cells from oxidative damage, commonly upregulated in response to inflammatory or therapeutic stress. 

### 4. Crosstalk & Interactions
The mechanisms are intrinsically linked. The p63/p53-driven differentiation program (evidenced by KRT17, SFN) establishes a basal epithelial state. This state, under the stress of combined chemo-immunotherapy, likely induces oxidative stress, leading to the upregulation of GPX2 to mitigate damage and preserve cell viability. SFN sits at the crossroads, potentially linking cell cycle arrest signals (from therapy or differentiation) to the stabilization of the epithelial phenotype. The keratin network (KRT6A-KRT17-KRT19) provides the physical scaffold that must be maintained despite this stress. 

### 5. Hypothesis
**What**: The post-treatment NMPR tumor epithelium is enriched for a basal-like cell state defined by keratin expression and an oxidative stress response. **So What**: This signature may represent a therapy-resistant epithelial population that survived neoadjuvant camrelizumab + chemotherapy. By reinforcing differentiation and activating antioxidant defenses (GPX2), these cells could evade therapy-induced cell death and immune recognition, contributing to the observed non-major pathologic response. This state is distinct from a proliferative, MPR/pCR-associated phenotype. 

### 6. Narrative Draft
In post-surgical samples from LUSC patients with a non-major pathologic response (NMPR) to neoadjuvant camrelizumab plus chemotherapy, we identified a dominant gene signature indicative of a resilient basal epithelial cell state. This state is characterized by the marked upregulation of structural keratins (KRT6A, KRT17, KRT19) and epithelial barrier components (CSTA, SFN), consistent with a well-differentiated squamous phenotype (supported by: Basal cell, Epithelial cell enrichments). Concurrent upregulation of the antioxidant enzyme GPX2 points to an active adaptive response to oxidative stress, likely induced by the therapeutic regimen. We propose that this coordinated program of enhanced structural integrity and detoxification may confer a survival advantage to a subset of tumor epithelial cells, allowing them to withstand chemo-immunotherapeutic pressure and persist, thereby underlying the NMPR outcome. This phenotype contrasts with the expected clearance of such epithelial compartments in major responders. 

### 7. Refined Regulatory Network
Key Interactions:
  TP63 -- KRT17 (activation) - Master regulator of basal cell identity; KRT17 is a canonical target defining squamous differentiation.
  TP63 -- KRT6A (activation) - Co-regulated with KRT17 as part of the p63-driven squamous differentiation program.
  TP53 -- SFN (activation) - SFN (14-3-3σ) is a direct transcriptional target of p53, induced during cell cycle arrest and epithelial differentiation.
  SFN -- Cell Cycle Arrest (regulation) - SFN protein binds to and sequesters cyclin-dependent kinases, contributing to G2/M arrest, a plausible state in therapy-exposed cells.
  Oxidative Stress -- GPX2 (induction) - GPX2 is a key epithelial-specific antioxidant enzyme induced by NRF2 signaling in response to oxidative stress from therapy.
  KRT17 -- KRT6A (co-complex) - Keratin 17 and Keratin 6A form intermediate filament heterodimers, constituting the core cytoskeletal module of this basal state.
  CSTA -- Epithelial Barrier (maintenance) - Cystatin A inhibits lysosomal cathepsins, protecting desmosomal proteins and maintaining epithelial integrity, a key feature of the enriched phenotype.

**Network Evidence:**
The refined network centers on two protein modules: 1) The **Keratin Cytoskeleton Module**, comprising the heterodimeric complex of KRT17 and KRT6A, likely paired with KRT19, which provides physical resilience. 2) The **Stress-Response Module**, where the p53 target SFN and the antioxidant GPX2 function in parallel to manage therapy-induced damage. TP63 acts as the inferred upstream hub initiating the keratin expression program, while environmental stress signals act as the upstream hub inducing GPX2. The co-expression of all these genes in the same cell cluster suggests an integrated program where differentiation and stress resistance are coordinately regulated to promote epithelial persistence. 

---

## Interpretation Result

### Cluster: 13

### 1. Overview
The enrichment results strongly indicate that the analyzed cell state is a myeloid-derived immune population, specifically exhibiting features of antigen-presenting cells (APCs) and innate immune activation. The top terms point to a macrophage/dendritic cell identity (supported by: Macrophage, Dendritic cell, Classical monocyte, Conventional dendritic cell 2(cDC2)), with a strong signature of immune effector functions and secretory activity (supported by: Secretory cell). The unexpected enrichment for 'Paneth cell' is interpreted as a spurious annotation due to shared secretory and antimicrobial gene modules with myeloid cells. The core signature is driven by genes involved in Fc receptor signaling (FCER1G, TYROBP), antigen presentation (HLA-DQA1, HLA-DQB1), and myeloid activation (FGL2, MS4A6A, PLEK, LCP1). 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor (TF) enrichments were provided in the list. However, key hub genes in the signature can infer potential upstream regulators. TYROBP (DAP12) is a critical signaling adaptor for multiple activating receptors on myeloid and NK cells, and its expression is often regulated by PU.1 (SPI1), a master regulator of myeloid lineage. The coordinated upregulation of HLA class II genes (HLA-DQA1, HLA-DQB1) suggests activity of the MHC class II transactivator (CIITA), which is induced by IFN-γ signaling. Therefore, the inferred regulatory axis involves PU.1-driven myeloid differentiation and IFN-γ-mediated activation of antigen presentation machinery. 

### 3. Key Mechanisms
1. **Innate Immune Activation & Phagocytosis**: Upregulation of Fcγ receptor subunit FCER1G and its signaling partner TYROBP indicates enhanced capacity for antibody-dependent cellular phagocytosis (ADCP) and inflammatory signaling (supported by: Macrophage, Myeloid cell, Hematopoietic cell). This is reinforced by PLEK (involved in membrane-cytoskeleton signaling) and LCP1 (L-Plastin, an actin-bundling protein critical for phagocytosis).
2. **Antigen Presentation & Adaptive Immune Interface**: High expression of HLA class II genes (HLA-DQA1, HLA-DQB1) defines an antigen-presenting phenotype, characteristic of macrophages and dendritic cells (supported by: Dendritic cell, Classical monocyte, cDC2). This positions this cell state to potentially engage with CD4+ T cells.
3. **Pro-inflammatory Secretory Phenotype**: The presence of FGL2 (a fibrinogen-like protein secreted by macrophages that can have immunoregulatory effects) and the 'Secretory cell' annotation suggest active cytokine or mediator secretion. GPR183 (EBI2) is a chemotactic receptor for oxysterols involved in immune cell positioning.
4. **Myeloid Lineage Identity**: The consistent co-enrichment of markers like MS4A6A (a macrophage marker), FCER1G, and TYROBP across multiple myeloid terms solidifies the core identity as a myeloid leukocyte. 

### 4. Crosstalk & Interactions
A core regulatory network centers on the TYROBP signaling hub. TYROBP, paired with receptors like TREM2 or SIGLECs, can activate SYK via ITAM motifs, leading to downstream activation of PLCγ2 (via PLEK) and cytoskeletal reorganization (via LCP1) for phagocytosis. This phagocytic activity is coupled to antigen processing and loading onto upregulated HLA class II molecules, linking innate sensing to adaptive immune presentation. Furthermore, secreted factors like FGL2 may feed back to modulate the local microenvironment. The GPR183 receptor could guide cellular migration within the tumor or lymphoid structures. Thus, the pathways describe an integrated module for antigen capture, processing, presentation, and potential modulation of the immune synapse. 

### 5. Hypothesis
**What**: A myeloid cell population in post-treatment non-major pathologic response (NMPR) LUSC exhibits a strong signature of activated antigen-presenting cells, with high phagocytic and HLA class II presentation machinery.
**So What**: This phenotype may represent a treatment-induced but insufficient immune activation state. The presence of such cells in NMPR (as opposed to MPR/pCR) suggests that despite successful myeloid recruitment and activation by ICB+chemotherapy, the adaptive immune response fails to achieve complete tumor clearance. This could be due to defective T cell priming, active immunosuppression (potentially hinted by FGL2), or compensatory resistance mechanisms. The population may thus signify a 'bottleneck' in the therapy response cascade. 

### 6. Narrative Draft
In post-surgical samples from LUSC patients with non-major pathologic response (NMPR) to neoadjuvant camrelizumab plus chemotherapy, we identified a cell state defined by a robust myeloid activation signature. Functional enrichment analyses revealed a phenotype characteristic of antigen-presenting macrophages or dendritic cells, marked by high expression of HLA class II genes (HLA-DQA1, HLA-DQB1), Fc receptor signaling components (FCER1G, TYROBP), and myeloid markers (MS4A6A, FGL2). This signature indicates strong innate immune activation, including enhanced potential for phagocytosis and antigen presentation. The presence of this activated myeloid phenotype in NMPR samples suggests that therapy can successfully recruit and activate myeloid lineages, but this alone is insufficient for a pathologic complete response. We hypothesize that this state may reflect an incomplete transition to effective adaptive immunity, potentially due to deficiencies in downstream T-cell engagement or the co-expression of immunomodulatory factors like FGL2. 

### 7. Refined Regulatory Network
Key Interactions:
  TYROBP -- FCER1G (signaling_complex) - Core ITAM-bearing signaling subunit (FCER1G) pairs with TYROBP (DAP12) to form activating receptor complexes on myeloid cells, driving phagocytosis and inflammatory responses.
  TYROBP -- PLEK (activation) - TYROBP-mediated SYK activation phosphorylates and activates PLEK, which is essential for downstream cytoskeletal reorganization and cellular activation.
  PLEK -- LCP1 (regulation) - PLEK-mediated signaling pathways regulate actin-binding proteins like LCP1, which is critical for phagocytic cup formation and cell motility.
  IFNGR1 -- HLA-DQA1 (transcriptional_activation) - Inferred interaction: IFN-γ signaling via its receptor is the primary inducer of MHC class II genes, including HLA-DQA1 and HLA-DQB1, through CIITA.
  IFNGR1 -- HLA-DQB1 (transcriptional_activation) - See above; coordinated upregulation of both HLA class II genes indicates a common IFN-γ-driven regulatory mechanism.
  FGL2 -- Immune Cells (modulation) - FGL2 is a secreted immunomodulatory protein from macrophages that can suppress T-cell and dendritic cell function, representing a potential feedback mechanism.
  GPR183 -- Cell Migration (regulation) - GPR183 responds to oxysterol gradients to direct immune cell positioning, potentially guiding this myeloid population within the tumor microenvironment.

**Network Evidence:**
The network is centered on the TYROBP/FCER1G ITAM signaling module, a well-defined protein complex that initiates a cascade involving SYK, PLEK, and LCP1 to execute phagocytosis and inflammatory responses—a core function of the enriched 'Macrophage' and 'Myeloid cell' terms. The coordinated upregulation of HLA-DQA1 and HLA-DQB1 forms a functional antigen presentation module. While not a physical complex, their co-regulation is a hallmark of competent antigen-presenting cells. The inclusion of FGL2 and GPR183 adds secretory and migratory modules, respectively, explaining the 'Secretory cell' annotation and providing mechanisms for environmental interaction. This integrated network supports the interpretation of a multifunctional, activated myeloid state. 

---

## Interpretation Result

### Cluster: 14

### 1. Overview
The functional enrichment analysis reveals a dominant and highly specific proliferative signature in the post-treatment, non-major pathologic response (NMPR) LUSC sample. The top enriched terms across multiple cell-type ontologies (e.g., 'Neural progenitor cell', 'Proliferative cell', 'MKI67+ progenitor cell') are overwhelmingly driven by a core set of 8-10 genes (CENPF, NUSAP1, KIF11, PCLAF, TOP2A, MKI67, HMGB2, STMN1, TMPO, SMC4) that are canonical markers of active cell cycle progression, specifically the G2/M and mitotic phases. The appearance of these genes in diverse cell-type contexts (e.g., 'Mesothelial cell', 'Fibroblast', 'CD8+ T cell') is an artifact of proliferation marker expression, not true lineage identity. The primary biological theme is thus uncontrolled cellular proliferation, with secondary themes of chromosome segregation, mitotic spindle function, and chromatin organization. 

### 2. Regulatory Drivers (TFs/Hubs)
While no specific transcription factors (TFs) are listed in the provided enrichment results, the gene set is classically regulated by the E2F family of transcription factors and their dimerization partners (DP), which are master regulators of S-phase and G2/M gene expression. The core proliferative genes (CENPF, NUSAP1, KIF11, TOP2A, MKI67) are well-established E2F target genes. The high-mobility group protein HMGB2 is also involved in chromatin remodeling during mitosis and can be regulated by cell cycle machinery. Therefore, the inferred master regulatory network is centered on E2F/DP activity, driving the expression of this coherent mitotic gene module. 

### 3. Key Mechanisms
1. **Active Cell Cycle & Mitosis**: This is the central mechanism, supported by the universal presence of core mitotic genes across all top terms. Key processes include: chromosome condensation and segregation (SMC4, CENPF), mitotic spindle formation and function (KIF11, NUSAP1), DNA topoisomerase activity (TOP2A), and proliferation marker expression (MKI67).
2. **Chromatin Organization & Replication**: Supported by genes like HMGB2 (chromatin architecture), TMPO (nuclear envelope reassembly), and TOP2A (DNA topology management during replication/segregation).
3. **Progenitor-like State**: The enrichment of terms like 'Neural progenitor cell' and 'Nephron progenitor cell' reflects the shared transcriptional program of highly proliferative, undifferentiated cells, which is captured by this core mitotic gene set rather than true lineage commitment. 

### 4. Crosstalk & Interactions
The crosstalk is intrinsic and co-regulatory within the mitotic program. The E2F-driven transcriptional module activates genes that encode proteins which must physically interact to execute mitosis. For example: KIF11 (a kinesin) functions on the mitotic spindle, requiring interaction with microtubules whose dynamics are influenced by STMN1. The condensin complex (containing SMC4) compacts chromosomes, while TOP2A resolves DNA tangles, and both are necessary for faithful segregation. CENPF localizes to kinetochores, linking chromosomes to the KIF11-containing spindle apparatus. This creates a tightly coupled network where transcriptional co-regulation enables physical protein complex formation and function. 

### 5. Hypothesis
**What**: The PostNMPR LUSC sample is characterized by a strikingly coherent transcriptional signature of active cell cycle progression and mitosis. **So What**: This persistent, high-level proliferative program in a post-treatment, non-responding tumor suggests a population of therapy-resistant cancer cells that have either evaded cell-cycle arrest or have rapidly resumed proliferation following neoadjuvant camrelizumab + chemotherapy. The dominance of this signature over immune or stromal activation programs implies that therapeutic failure in this context may be driven primarily by intrinsic tumor cell proliferative resilience rather than, for example, a suppressive immune microenvironment. 

### 6. Narrative Draft
In the post-treatment non-major pathologic response (NMPR) LUSC sample, functional enrichment analysis revealed a dominant signature of cellular proliferation. The top enriched terms, including 'Neural progenitor cell', 'Proliferative cell', and 'MKI67+ progenitor cell', were all driven by a core module of genes involved in the G2/M phase and mitosis (CENPF, NUSAP1, KIF11, TOP2A, MKI67). This pattern indicates that a significant cell population within the treatment-resistant tumor is actively cycling. The recurrence of this proliferative gene set across annotations for diverse cell types (e.g., fibroblasts, T cells) is a known artifact of proliferation marker expression in single-cell data, further underscoring the strength of the cell-cycle signal. The persistence of such a robust mitotic program after combination chemo-immunotherapy suggests that these cancer cells possess mechanisms to bypass therapy-induced cell-cycle checkpoints, representing a potential axis of resistance in NMPR cases. 

### 7. Refined Regulatory Network
Key Interactions:
  E2F1/DP1 -- MKI67 (transcriptional_activation) - MKI67 is a canonical E2F target and the top upregulated gene, serving as the key marker of proliferation driving multiple enrichment terms.
  E2F1/DP1 -- TOP2A (transcriptional_activation) - TOP2A is a core E2F target essential for DNA decatenation in mitosis, present in nearly all top enrichment terms.
  E2F1/DP1 -- CENPF (transcriptional_activation) - CENPF is a mitotic kinetochore protein and E2F target, present in all top enrichment terms and a key hub.
  E2F1/DP1 -- KIF11 (transcriptional_activation) - KIF11 is a mitotic kinesin and E2F target, crucial for spindle formation, and is highly upregulated.
  CENPF -- Microtubules/KIF11 (physical_binding) - CENPF localizes to kinetochores and interacts with the mitotic spindle, linking chromosome segregation to spindle machinery.
  TOP2A -- DNA (enzymatic_activity) - TOP2A resolves DNA topological problems during chromosome segregation, a function essential for the mitotic process highlighted by the enrichments.
  SMC4 -- Chromatin (complex_formation) - SMC4 is part of the condensin complex required for chromosome condensation, a critical step in mitosis represented in the 'Neural progenitor cell' enrichment.
  STMN1 -- Microtubules (destabilization) - STMN1 regulates microtubule dynamics, facilitating spindle reorganization during mitosis, and appears in immune-cell proliferative terms (e.g., 'Germinal center B cell').

**Network Evidence:**
The refined network centers on the E2F transcriptional module activating a coherent protein interaction network that executes mitosis. Key functional modules include: 1) The **Chromosome Segregation Module**, comprising the condensin complex (SMC4) for condensation and the kinetochore protein CENPF for microtubule attachment. 2) The **Mitotic Spindle Module**, involving the motor protein KIF11 and the regulator STMN1. 3) The **DNA Topology Module**, centered on TOP2A. These modules are not isolated; they are co-regulated (by E2F) and their physical interactions (e.g., CENPF-KIF11 linking chromosomes to spindle) are necessary for the proliferative phenotype captured by the enrichment results. The network is pruned to these core interactions because they directly explain the universal presence of these genes across the diverse 'proliferative cell' enrichment terms. 

---

## Interpretation Result

### Cluster: 15

### 1. Overview
The enrichment analysis identifies a dominant mesenchymal/stromal phenotype, specifically a cancer-associated fibroblast (CAF)-like state, within the post-treatment, non-major pathologic response (NMPR) LUSC tumor microenvironment. The top enriched terms (Fibroblast, Myofibroblast, Pericyte, Cancer-associated fibroblast) and the core gene set (COL1A2, COL3A1, SPARC, RGS5, CALD1, MYL9) collectively point to an active, extracellular matrix (ECM)-producing, and contractile stromal cell population. This is consistent with a fibrotic, desmoplastic tumor stroma that may be associated with treatment resistance. 

### 2. Regulatory Drivers (TFs/Hubs)
No direct transcription factor (TF) enrichments were provided in the top terms. However, key hub genes in the network, such as SPARC and IGFBP7, are known to be regulated by and to influence TGF-β signaling, a master regulator of fibroblast activation and fibrosis. The high expression of MYL9 and CALD1 suggests potential regulation by serum response factor (SRF) and myocardin-related transcription factors (MRTFs), which are central to actin cytoskeleton remodeling and the contractile myofibroblast phenotype. Thus, the inferred upstream drivers are the TGF-β pathway and the SRF/MRTF axis, which coordinately drive the expression of the core ECM and cytoskeletal genes observed. 

### 3. Key Mechanisms
1. **Extracellular Matrix Deposition and Remodeling**: This is the most prominent mechanism, driven by high expression of fibrillar collagens (COL1A2, COL3A1) and matricellular proteins (SPARC, SPARCL1, IGFBP7) (supported by: Fibroblast, Mesenchymal cell, Fibrocartilage chondrocyte).
2. **Myofibroblast Differentiation and Contractility**: Evidenced by the co-expression of smooth muscle/contractile genes (RGS5, MYL9, CALD1) with ECM components (supported by: Myofibroblast, Pericyte, Smooth muscle cell).
3. **Cancer-Associated Fibroblast (CAF) Identity**: The combination of mechanisms 1 and 2 defines a prototypical CAF state, which is explicitly supported by the 'Cancer-associated fibroblast' enrichment term. The presence of MGP and DCLK1+ progenitor cell terms may hint at heterogeneous CAF subpopulations or plasticity. 

### 4. Crosstalk & Interactions
The core gene network forms a tightly interconnected functional module. SPARC and IGFBP7 are matricellular proteins that can modulate TGF-β bioavailability and integrin signaling, thereby feeding back to enhance ECM production and fibroblast activation. The contractile apparatus (MYL9, CALD1) is physically and functionally linked to the ECM via integrin-mediated focal adhesions, creating a mechanosignaling loop. RGS5, a regulator of G-protein signaling in pericytes, may modulate PDGFRβ and other GPCR pathways that influence stromal cell proliferation and migration. This integrated network suggests a self-reinforcing, activated stromal program. 

### 5. Hypothesis
**What**: In post-surgical LUSC samples from patients with a non-major pathologic response (NMPR) to neoadjuvant camrelizumab + chemotherapy, we identify a resilient population of activated, matrix-producing, and contractile cancer-associated fibroblasts (CAFs).
**So What**: This persistent CAF-rich, desmoplastic stroma may contribute to treatment resistance by creating a physical and biochemical barrier that impedes drug penetration and immune cell infiltration, promoting a tumor-protective niche. The presence of this phenotype post-treatment suggests stromal reprogramming as a potential mechanism of adaptive resistance to combination immunotherapy and chemotherapy. 

### 6. Narrative Draft
In post-treatment LUSC tumors from NMPR patients, a dominant cell state was characterized by high expression of canonical mesenchymal and extracellular matrix (ECM) genes. Functional enrichment robustly identified this population as fibroblasts, with strong signatures for myofibroblast differentiation, pericyte-like features, and a cancer-associated fibroblast (CAF) phenotype. The core gene module included fibrillar collagens (COL1A2, COL3A1), matricellular regulators (SPARC, IGFBP7), and contractile cytoskeletal elements (MYL9, CALD1, RGS5). This signature is indicative of an active, fibrotic stroma. Given the treatment context, the persistence of this CAF-enriched, desmoplastic microenvironment in non-responders suggests that stromal activation may be a key determinant of resistance to neoadjuvant immune-checkpoint blockade and chemotherapy, possibly through ECM-mediated exclusion of cytotoxic lymphocytes and reduced chemotherapeutic efficacy. 

### 7. Refined Regulatory Network
Key Interactions:
  TGFB1 -- COL1A2 (activation) - TGF-β is the canonical inducer of collagen expression and fibroblast activation, central to the observed phenotype.
  TGFB1 -- SPARC (activation) - SPARC is a known TGF-β target gene and a key matricellular protein in the enriched set.
  SRF/MRTF -- MYL9 (activation) - MYL9 is a direct transcriptional target of SRF/MRTF, linking cytoskeletal tension to gene expression in myofibroblasts.
  SRF/MRTF -- CALD1 (activation) - Caldesmon (CALD1) is involved in smooth muscle contraction and is regulated by the SRF pathway.
  TGFB1 -- SPARC (modulation) - SPARC can sequester and modulate the activity of TGF-β, creating a positive feedback loop for stromal activation.
  COL1A2 -- Integrins (binding) - Collagen I is a major ligand for integrins, activating downstream mechanotransduction pathways that sustain the fibroblast state.
  RGS5 -- GPCR signaling (inhibition) - RGS5 modulates G-protein signaling, potentially affecting PDGFRβ and other pathways critical for pericyte/stromal cell function.

**Network Evidence:**
The provided gene set forms a coherent protein-protein interaction (PPI) module centered on ECM-structural (COL1A2, COL3A1) and ECM-regulatory (SPARC, IGFBP7) proteins. SPARC is a hub known to interact with multiple collagens and TGF-β. The contractile module (MYL9, CALD1) is functionally linked; MYL9 (myosin light chain) and CALD1 (caldesmon) are components of the actomyosin apparatus. While not all direct physical interactions are present in the 10-gene list, their co-expression and functional enrichment define a core 'ECM-contractility' module. The inclusion of RGS5 connects this module to GPCR-mediated signaling pathways often involved in stromal cell recruitment and vascular regulation. 

---

## Interpretation Result

### Cluster: 16

### 1. Overview
The enrichment analysis reveals a dominant secretory epithelial cell phenotype in the post-treatment, non-major pathologic response (NMPR) LUSC sample. The top enriched terms are cell type annotations (Club cell, Secretory cell, Goblet cell, Epithelial cell), indicating the cluster's identity rather than a dynamic biological process. This is driven by strong upregulation of genes encoding secreted proteins and mucosal defense factors (e.g., SCGB3A1, BPIFB1, LTF, SLPI, PIGR). The results point to a persisting or expanding population of airway secretory epithelial cells in the tumor microenvironment post neoadjuvant chemoimmunotherapy in non-responders. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor (TF) enrichments were provided in the top terms. However, based on known biology of the key marker genes, potential inferred master regulators include: 1) **SPDEF**, a master regulator of secretory cell differentiation and goblet cell metaplasia, known to directly activate genes like AGR2, PIGR, and WFDC2. 2) **FOXA1/FOXA2**, which regulate Clara/Club cell fate and SCGB3A1 expression. 3) **STAT6** (IL-4/IL-13 signaling) and **NF-κB** (inflammatory signaling), which can induce many of the upregulated innate defense genes (e.g., PIGR, SLPI, LTF). The enrichment of secretory cell identity suggests these TFs are active, driving a transcriptional program of mucosal differentiation and host defense. 

### 3. Key Mechanisms
The major biological themes are: 1) **Airway Secretory Cell Differentiation** (supported by: Club cell, Secretory cell, Goblet cell). The co-expression of classic Club cell markers (SCGB3A1, BPIFB1) and goblet cell markers (AGR2, PIGR, MUC5B) suggests a mixed or transitional secretory state, potentially indicative of airway remodeling. 2) **Mucosal Innate Immunity and Barrier Function** (supported by: Epithelial cell). Upregulated genes encode proteins with direct antimicrobial (LTF, SLPI), anti-protease (SLPI, WFDC2), and immunoglobulin transport (PIGR) functions, constituting a frontline defense module. 3) **Stress Response and Tissue Protection** (inferred from gene function). Genes like CLU (clusterin) and SCGB3A1 have anti-inflammatory and cytoprotective roles, suggesting an adaptive response to treatment-induced stress. 

### 4. Crosstalk & Interactions
The pathways are intrinsically linked through a core epithelial differentiation and defense program. The secretory differentiation program (driven by SPDEF/FOXA factors) directly activates the expression of the innate immune effectors (e.g., PIGR, SLPI). Conversely, inflammatory signals (e.g., TNF, IL-1, IL-13) via NF-κB and STAT6 can reinforce secretory differentiation and goblet cell metaplasia, creating a positive feedback loop. The protein products (e.g., SLPI, LTF) can further modulate the local immune microenvironment by inhibiting neutrophil proteases and sequestering iron, potentially influencing the efficacy of immunotherapy. 

### 5. Hypothesis
**What**: The analyzed cell cluster in post-treatment NMPR LUSC exhibits a strong gene signature of airway secretory epithelial cells (Club/goblet) and mucosal defense. **So What**: This suggests that in patients who do not achieve a major pathologic response to neoadjuvant camrelizumab + chemotherapy, the residual tumor ecosystem may be characterized by a remodeled, protective epithelial compartment. This secretory, defense-oriented phenotype could represent a mechanism of therapy resistance, potentially by creating a physical and biochemical barrier that limits drug penetration or immune cell infiltration/function, and/or by promoting a tumor-protective, anti-inflammatory microenvironment. 

### 6. Narrative Draft
In the post-surgical sample from a non-major pathologic responder (NMPR) with LUSC treated with neoadjuvant camrelizumab and chemotherapy, we identified a prominent cell state defined by markers of airway secretory epithelial differentiation. This cluster was highly enriched for genes characteristic of Club cells (SCGB3A1, BPIFB1), goblet cells (AGR2, PIGR), and broad epithelial defense functions (LTF, SLPI, WFDC2). The concerted upregulation of this mucosal defense program, including antimicrobials, anti-proteases, and immunoglobulin transport, indicates an active innate immune role for these epithelial cells within the treatment-resistant tumor microenvironment. The persistence of this differentiated, barrier-forming phenotype post-treatment may reflect a failure of therapy to eliminate tumor-supportive stromal niches or an adaptive tissue protection response that inadvertently shields residual tumor cells. This signature warrants investigation as a potential biomarker for, or mediator of, resistance to combination chemoimmunotherapy in LUSC. 

### 7. Refined Regulatory Network
Key Interactions:
  SPDEF -- AGR2 (activation) - SPDEF is a master transcriptional regulator of goblet cell differentiation and directly activates AGR2 expression.
  SPDEF -- PIGR (activation) - SPDEF is known to regulate genes involved in mucosal immunity, including PIGR.
  FOXA1/FOXA2 -- SCGB3A1 (activation) - Forkhead box A factors are critical for Club cell lineage specification and SCGB3A1 transcription.
  NF-κB -- SLPI (activation) - NF-κB signaling, induced by TNF/IL-1, is a key activator of SLPI expression in epithelial cells.
  NF-κB -- PIGR (activation) - Inflammatory signaling via NF-κB potently upregulates PIGR expression.
  STAT6 -- BPIFB1 (activation) - IL-4/IL-13 signaling via STAT6 drives expression of BPI-fold containing genes like BPIFB1 in airway epithelium.
  NF-κB -- SLPI (inhibition) - SLPI protein can inhibit NF-κB activation, representing a negative feedback loop in inflammation.
  LTF -- Iron (binding) - LTF (lactoferrin) protein sequesters iron, exerting antimicrobial and immunomodulatory effects.

**Network Evidence:**
The refined network centers on a protein-functional module of secreted mucosal defense factors (SLPI, LTF, PIGR, SCGB3A1) under the coordinated transcriptional control of lineage-determining TFs (SPDEF, FOXA) and inflammatory signal transducers (NF-κB, STAT6). This constitutes a coherent 'secretory-innate defense module' commonly activated in airway epithelium during injury, infection, or remodeling. Key hubs in this network are the transcription factor SPDEF, which integrates differentiation signals to drive multiple effector genes (AGR2, PIGR), and NF-κB, which links external inflammatory cues to the expression of defense genes (SLPI, PIGR). The presence of negative regulation (SLPI inhibiting NF-κB) suggests a built-in feedback mechanism to prevent excessive inflammation, which may be critical in the post-treatment context. 

---

## Interpretation Result

### Cluster: 17

### 1. Overview
The enrichment analysis strongly identifies a mast cell signature (Mast cell, Basophil, Immune cell, Granulocyte-monocyte progenitor) as the dominant biological identity of this cluster. The core gene set (TPSAB1, TPSB2, CPA3, MS4A2, KIT, IL1RL1, HPGDS, SLC18A2, VWA5A) defines a terminally differentiated, tissue-resident mast cell population with potent effector functions, including protease release (TPSAB1/TPSB2/CPA3), histamine secretion (MS4A2), and eicosanoid production (HPGDS). The co-enrichment for 'T helper 2 (Th2) cell' and 'CD8+ T cell' terms reflects shared gene expression (e.g., IL1RL1, KIT) indicative of a Th2-skewed immune microenvironment, a known context for mast cell activity. 

### 2. Regulatory Drivers (TFs/Hubs)
Direct transcription factor enrichment was not provided in the top terms. However, the master regulator driving this phenotype can be inferred from the network hub gene KIT. KIT (CD117) signaling, primarily via its ligand Stem Cell Factor (SCF), is the critical determinant of mast cell development, survival, and tissue homing. The high expression of KIT, along with the full mast cell protease and mediator suite, indicates active KIT signaling is the upstream driver maintaining this mature mast cell state. The IL1RL1 (IL-33 receptor) enrichment further points to IL-33/ST2 signaling as a key co-regulator of mast cell activation in tissue. 

### 3. Key Mechanisms
1. **Mast Cell Effector Secretion**: The cluster is defined by genes for pre-formed granule mediators: tryptases (TPSAB1, TPSB2), chymase (CMA1, implied by mast cell identity), and carboxypeptidase A3 (CPA3). The histamine receptor subunit MS4A2 (FcεRIβ) is also highly expressed. 2. **Mast Cell Development & Survival**: High KIT expression signifies dependency on SCF for survival. 3. **Eicosanoid & Cytokine Response Machinery**: HPGDS encodes hematopoietic prostaglandin D synthase, a key enzyme for producing PGD2, a mast cell-derived mediator involved in Th2 responses. IL1RL1 is the receptor for the alarmin IL-33, a potent activator of mast cells in tissue. 4. **Vesicular Monoamine Transport**: SLC18A2 (VMAT2) is involved in packaging biogenic amines like histamine and serotonin into secretory granules. 

### 4. Crosstalk & Interactions
The mast cell population is positioned for extensive crosstalk within the tumor microenvironment. Through IL-33/IL1RL1 signaling, mast cells can be activated by damaged epithelial or stromal cells. Once activated, they release PGD2 (via HPGDS) which can promote Th2 polarization and immunosuppression. The secreted proteases (TPSAB1/B2, CPA3) can remodel the extracellular matrix, potentially influencing fibrosis and tumor invasion. The expression of KIT makes these cells responsive to SCF from tumor and stromal cells, creating a feed-forward survival loop. The shared 'Th2 cell' signature gene IL1RL1 suggests a reciprocal activation axis between mast cells and Th2 cells. 

### 5. Hypothesis
**What**: A distinct population of tissue-resident, effector-competent mast cells is present in post-treatment, non-major pathologic response (NMPR) LUSC tumors. **So What**: This mast cell signature may indicate an active, Th2-skewed, and pro-fibrotic tumor microenvironment that persists after neoadjuvant chemo-immunotherapy. Mast cell-derived mediators (proteases, PGD2, histamine) could contribute to treatment resistance by promoting immune suppression, tissue remodeling, and fibrosis, thereby limiting the efficacy of ICB+chemotherapy in these NMPR patients. 

### 6. Narrative Draft
In post-surgical samples from LUSC patients with a non-major pathologic response (NMPR) to neoadjuvant camrelizumab plus chemotherapy, we identified a cell cluster defined by a robust mast cell signature. This population expresses the full mast cell lineage marker KIT (CD117) and a suite of effector molecules, including the proteases TPSAB1, TPSB2, and CPA3, the histamine pathway component MS4A2, the prostaglandin-D2 synthase HPGDS, and the IL-33 receptor IL1RL1. The enrichment of terms related to basophils and granulocyte-monocyte progenitors reflects shared lineage markers, but the co-expression of this mature mediator suite confirms a terminally differentiated mast cell state. The presence of this signature, particularly the IL-33/IL1RL1 axis and PGD2-synthesizing enzyme, suggests an activated mast cell population within a Th2-type microenvironment. Given the known roles of mast cells in promoting fibrosis, angiogenesis, and immunosuppression, their persistence in NMPR tumors post-treatment may represent a novel cellular mechanism of resistance to combination chemo-immunotherapy in LUSC. 

### 7. Refined Regulatory Network
Key Interactions:
  KIT -- TPSAB1 (activation) - KIT signaling is essential for mast cell development, survival, and maturation, leading to the expression of mast cell-specific proteases like TPSAB1.
  KIT -- CPA3 (activation) - As a core mast cell lineage driver, KIT signaling sustains the expression of granule components including CPA3.
  IL1RL1 -- HPGDS (activation) - IL-33 signaling via IL1RL1 is a potent activator of mast cells, inducing the production of lipid mediators like PGD2, synthesized by HPGDS.
  IL1RL1 -- TPSAB1 (activation) - IL-33/IL1RL1 signaling can trigger mast cell degranulation and potentially upregulate protease expression as part of the activation program.
  MS4A2 -- SLC18A2 (co-complex) - MS4A2 is a subunit of the high-affinity IgE receptor (FcεRI), while SLC18A2 packages amines into granules; both are critical for IgE-mediated mast cell degranulation, a core functional module.
  TPSAB1 -- TPSB2 (co-complex) - TPSAB1 and TPSB2 form tetramers to create active tryptase, representing a key effector protein complex of mast cells.

**Network Evidence:**
The refined network centers on two key functional modules: 1) The **KIT-driven survival/maturation module**, with KIT as the hub regulating the expression of terminal differentiation markers (TPSAB1, CPA3). 2) The **mast cell granule/activation module**, comprising the tryptase complex (TPSAB1-TPSB2) and the interconnected histamine response machinery (MS4A2 and SLC18A2). The IL1RL1 node integrates an external alarmin signal (IL-33) into this network, activating the mediator production pathways (e.g., HPGDS). This network encapsulates the core biology of a tissue-resident, SCF-dependent, and IL-33-responsive mast cell poised for effector function. 

---

## Interpretation Result

### Cluster: 18

### 1. Overview
The enrichment analysis, while not yielding significant pathway terms, reveals a set of highly upregulated marker genes in a post-treatment, non-major pathologic response (NMPR) LUSC sample. The gene signature points to a coordinated program involving neuronal/axonal guidance cues (TUSC1, NTRK2, UCHL1), stemness and lineage plasticity (SOX2, PTHLH), and oxidative/detoxification stress responses (GPX2, ALDH3A1, AKR1C2). This suggests a cell state adapted to treatment pressure, characterized by developmental reprogramming and survival mechanisms. 

### 2. Regulatory Drivers (TFs/Hubs)
SOX2 is the central inferred transcriptional driver within the marker list. As a master regulator of stemness and lineage plasticity in squamous cell carcinomas, its high upregulation (log2FC=3.81) is a likely driver of the observed gene expression profile, potentially regulating genes like PTHLH and CTTN. While not present in the provided gene list, the upregulation of the neurotrophic receptor NTRK2 suggests potential downstream activation of transcription factors like CREB, which can promote survival and plasticity. 

### 3. Key Mechanisms
1. **Neuronal-like Plasticity and Axon Guidance**: Upregulation of TUSC1 (tumor suppressor candidate 1, involved in neuronal differentiation), NTRK2 (neurotrophic tyrosine receptor kinase 2), and UCHL1 (neuronal deubiquitinase) indicates activation of neuronal guidance and differentiation pathways, a known feature of epithelial-mesenchymal plasticity and invasion in LUSC. 2. **Squamous Stemness and Lineage Specification**: High expression of SOX2 (key TF for squamous lineage) and PTHLH (parathyroid hormone-like hormone, involved in squamous differentiation and bone metastasis) points to a dedifferentiated, stem-like state. 3. **Treatment Resistance and Detoxification**: Elevated GPX2 (glutathione peroxidase 2), ALDH3A1 (aldehyde dehydrogenase 3A1), and AKR1C2 (aldo-keto reductase family 1 member C2) constitute a robust defense module against oxidative stress and chemotherapeutic agents, likely contributing to the NMPR phenotype. 

### 4. Crosstalk & Interactions
The core network likely centers on SOX2, which can promote expression of detoxification enzymes (like ALDHs) and influence cell adhesion/migration via targets like CTTN (cortactin). The neuronal module (NTRK2, UCHL1) may interact with the stemness module, as neuronal signaling pathways can promote cancer stem cell properties. Furthermore, the oxidative stress response (GPX2, ALDH3A1) provides a permissive environment for the survival of these plastic, SOX2-high cells under treatment-induced stress. 

### 5. Hypothesis
**What**: The post-treatment NMPR LUSC cell state is defined by the co-upregulation of a SOX2-driven stemness program, neuronal guidance molecules, and a potent detoxification system. **So What**: This tripartite signature represents an adaptive, resilient cell state that evades immune-chemo combination therapy. The neuronal/axonal guidance component may facilitate pro-invasive behavior and niche interactions, while the detoxification enzymes directly neutralize treatment-induced oxidative damage. Together, this program enables tumor cell persistence and may serve as a functional biomarker and therapeutic target for residual disease in NMPR patients. 

### 6. Narrative Draft
In post-surgical samples from LUSC patients with a non-major pathologic response (NMPR) to neoadjuvant camrelizumab plus chemotherapy, we identified a distinct transcriptional signature in specific cell clusters. This signature was not associated with classical proliferative or immune pathways but was instead characterized by marked upregulation of genes involved in neuronal differentiation and axon guidance (TUSC1, NTRK2, UCHL1), squamous stemness and lineage specification (SOX2, PTHLH), and oxidative/detoxification stress responses (GPX2, ALDH3A1, AKR1C2). The concurrent elevation of SOX2, a master regulator of lung squamous cell identity, and multiple aldehyde/dehydrogenase enzymes suggests a treatment-resistant, plastic cell state that utilizes developmental reprogramming and enhanced cytoprotection to survive therapy. This resilient phenotype may underlie the persistence of residual tumor cells in NMPR patients and pinpoint mechanisms of adaptive resistance to combined immune checkpoint blockade and chemotherapy. 

### 7. Refined Regulatory Network
Key Interactions:
  SOX2 -- PTHLH (transcriptional activation) - SOX2 is a known transcriptional regulator of PTHLH, a key factor in squamous differentiation and bone metastasis, linking stemness to lineage-specific outcomes.
  SOX2 -- ALDH3A1 (transcriptional activation) - SOX2 has been shown to regulate aldehyde dehydrogenase isoforms, connecting stemness to detoxification and treatment resistance.
  NTRK2 -- UCHL1 (signaling cascade) - NTRK2 neurotrophic signaling can influence neuronal protein stability and function, potentially regulating UCHL1 activity, representing a core neuronal plasticity module.
  GPX2 -- ALDH3A1 (functional cooperation) - Both are key components of the cellular antioxidant defense system, working in concert to mitigate oxidative stress induced by chemotherapy.
  CTTN -- UCHL1 (potential complex) - Cortactin (CTTN) is involved in cytoskeletal dynamics and invasion; UCHL1 deubiquitinase activity can stabilize such proteins, suggesting a functional interaction promoting motility.

**Network Evidence:**
The refined network highlights two core functional modules: 1) A **SOX2-centered regulatory module** linking stemness (SOX2) to differentiation (PTHLH) and detoxification (ALDH3A1). 2) A **neuronal plasticity and survival module** centered on the NTRK2 receptor and its potential downstream effects on proteins like UCHL1. The co-expression of these modules with the antioxidant enzymes GPX2 and AKR1C2 forms a cohesive survival network. The inclusion of CTTN, a cytoskeletal regulator often overexpressed in cancers, bridges invasion to the stability mechanisms potentially governed by UCHL1, illustrating how these pathways may converge to promote a persistent, treatment-evading cell state. 

---

## Interpretation Result

### Cluster: 19

### 1. Overview
The enrichment results unambiguously identify the cell cluster as a highly activated, cytotoxic, and exhausted T lymphocyte population. The dominant signatures are for CD8+ T cells, cytotoxic cells, and natural killer cells, driven by a core set of cytotoxic granule proteins (GZMB, GZMA, GNLY, NKG7) and T cell surface markers (CD2, CD7, TRBC2, TIGIT, CTLA4). Concurrent enrichment for 'Exhausted CD8+ T cell' and 'Regulatory T(Treg) cell' phenotypes indicates a state of functional dysregulation commonly associated with chronic antigen exposure in the tumor microenvironment. This profile is characteristic of tumor-infiltrating lymphocytes (TILs) in a post-treatment, non-major pathologic response (NMPR) setting. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor (TF) enrichment terms (e.g., from ChEA) are provided in the list. However, key immune-regulatory genes with known roles in T cell state determination are present. CTLA4 and TIGIT are critical immune checkpoint receptors and transcriptional targets of exhaustion-associated TFs like NFAT, TOX, and NR4A. Their high expression, alongside cytotoxic effectors, suggests a co-expression program driven by these master regulators of T cell dysfunction. The sustained expression of cytotoxic modules (GZMB, NKG7) may be maintained by transcription factors like T-BET (TBX21) and EOMES, which are central to effector differentiation. 

### 3. Key Mechanisms
1. **Cytotoxic Effector Function**: The core mechanism is mediated by granzyme (GZMA, GZMB) and granulysin (GNLY) release, supported by strong enrichment for 'Cytotoxic T cell', 'Cytotoxic cell', and 'Effector CD8 T cell' (supported by: Cytotoxic T cell, Cytotoxic cell, Effector CD8 T cell).
2. **T Cell Exhaustion/Dysfunction**: Co-expression of inhibitory receptors TIGIT and CTLA4 with cytotoxic genes defines a partially exhausted, yet still cytotoxic, state typical of tumor-reactive T cells (supported by: Exhausted CD8+ T cell, Exhausted T(Tex) cell, Foxp3+ regulatory T cell).
3. **Broad T/NK Cell Lineage**: The presence of pan-T cell (CD2, CD7, TRBC2, IL32), NK cell (NKG7, GNLY), and even γδ T cell markers indicates potential plasticity or a shared activation program across cytotoxic lymphocytes (supported by: T cell, Natural killer cell, Gamma delta(γδ) T cell, CD4+ T cell). 

### 4. Crosstalk & Interactions
The network centers on the integration of activation and inhibition signals. The cytotoxic module (GZMB/GZMA/GNLY/NKG7) and the inhibitory receptor module (TIGIT/CTLA4) are co-expressed, representing the 'checkpoint-positive cytotoxic' phenotype. CD2 and CD7, as broad T cell co-stimulatory molecules, likely provide basal activation signals. IL32 is a pro-inflammatory cytokine that can amplify immune responses. This crosstalk creates a push-pull dynamic: persistent antigen (implied by post-treatment NMPR) drives both cytotoxic effector function and the upregulation of feedback inhibitory pathways to prevent immunopathology, leading to a state of restrained cytotoxicity. 

### 5. Hypothesis
**What**: The cluster is a population of tumor-infiltrating, antigen-experienced CD8+ T cells co-expressing high levels of cytotoxic effector molecules and immune checkpoint receptors.
**So What**: In the post-surgical, NMPR context of neoadjuvant camrelizumab + chemotherapy in LUSC, this phenotype likely represents a 'bystander' or 'terminally exhausted' T cell state that failed to achieve effective tumor clearance. The sustained but dysregulated cytotoxicity may contribute to tissue inflammation without productive tumor killing, explaining the lack of major pathologic response. This state may be a biomarker of resistance to combination ICB/chemotherapy. 

### 6. Narrative Draft
Single-cell analysis of post-treatment LUSC samples from non-responders (NMPR) revealed a dominant T cell cluster characterized by a potent yet dysregulated cytotoxic signature. This population was definitively annotated as CD8+ T cells and cytotoxic lymphocytes, marked by high expression of granzymes (GZMA, GZMB), granulysin (GNLY), and the cytolytic component NKG7. Strikingly, these cells concurrently expressed the exhaustion-associated immune checkpoint receptors TIGIT and CTLA4, aligning with enrichment for 'Exhausted CD8+ T cell' and 'Treg' phenotypes. This co-expression pattern defines a state of 'restrained cytotoxicity' often observed in chronic viral infections and cancer. The presence of this phenotype post-neoadjuvant camrelizumab (a PD-1 inhibitor) suggests that alternative inhibitory pathways (TIGIT, CTLA4) may compensate to limit the efficacy of PD-1 blockade, contributing to the observed non-major pathologic response. The shared expression of NK cell-associated genes (e.g., GNLY, NKG7) further suggests a convergent, innate-like effector program in these tumor-infiltrating T cells. 

### 7. Refined Regulatory Network
Key Interactions:
  CTLA4 -- CD80/CD86 (inhibition) - CTLA4 is a high-affinity inhibitory receptor that outcompetes CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, delivering a dominant negative signal to suppress T cell activation. Its high expression is a hallmark of exhaustion.
  TIGIT -- CD155 (inhibition) - TIGIT binds to CD155 (PVR) on tumor and dendritic cells, directly inhibiting NK and T cell cytotoxicity and cytokine production. It is a key alternative immune checkpoint co-expressed with PD-1.
  GZMB -- Caspase Cascade (activation) - Granzyme B is a serine protease delivered into target cells to initiate apoptosis primarily via caspase-dependent pathways. It is a core effector molecule of cytotoxic lymphocytes.
  NKG7 -- Granule Exocytosis (component) - NKG7 is a critical component of the cytotoxic granule membrane, essential for the maturation, polarization, and exocytosis of granules containing GZMB and GNLY.
  CD2 -- CD58 (activation) - CD2-CD58 interaction provides a potent co-stimulatory signal that lowers the threshold for T cell activation and stabilizes the immunological synapse, supporting the activated state of this cluster.

**Network Evidence:**
The network describes a functional module centered on cytotoxic granule exocytosis (NKG7-GZMB/GZMA-GNLY) and a parallel module of surface inhibitory receptors (CTLA4, TIGIT). These two modules are co-expressed in the same cell population, as evidenced by their presence in the same gene list for terms like 'Exhausted CD8+ T cell'. This forms a core signaling paradox: the machinery for target cell killing is present and transcriptionally active, but its execution is likely restrained by the co-expressed inhibitory signals. CD2 acts as a foundational co-stimulatory anchor, providing the necessary initial activation signal that precedes the induction of both effector and exhaustion programs. 

---

## Interpretation Result

### Cluster: 20

### 1. Overview
The enrichment results strongly indicate a myeloid cell population, specifically neutrophils, with signatures of activation, chemotaxis, and immunosuppressive potential. The dominant identity is 'Neutrophil' (9/9 genes, p.adjust: 3.84e-14), supported by core markers like S100A8/A9, FCGR3B, CXCR2, CSF3R, and SELL. Concurrent enrichment for 'Myeloid-derived suppressor cell (MDSC)', 'Classical monocyte', and specific dendritic cell subsets (e.g., 'CD1C+ B dendritic cell', 'DC3') suggests phenotypic plasticity or a mixed myeloid state commonly associated with cancer. The high log2FC of these genes in a post-treatment, non-major pathologic response (NMPR) LUSC sample points to a treatment-resistant, pro-tumorigenic myeloid compartment. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor (TF) enrichments were provided in the list. However, key signaling receptors act as master regulators of the observed state. CSF3R (Granulocyte Colony-Stimulating Factor Receptor), with high expression (log2FC:7.29), is a central driver of granulopoiesis and neutrophil activation (supported by enrichment in 'Neutrophil', 'Granulocyte'). CXCR2 (log2FC:9.87) is the master chemokine receptor for neutrophil recruitment and retention. The co-expression of S100A8/A9, which can activate NF-κB and MAPK pathways, suggests an autocrine/paracrine inflammatory feedback loop that may sustain this myeloid state. While not listed, the activity of SPI1 (PU.1) and C/EBP family TFs can be inferred as upstream regulators of this core myeloid gene set. 

### 3. Key Mechanisms
Three interconnected mechanisms are evident: 1) **Neutrophil Activation & Recruitment**: High expression of CXCR2, SELL (L-selectin), and FPR1 (fMLP receptor) indicates strong chemotactic and migratory capacity (supported by: 'Neutrophil', 'Myeloid cell'). 2) **Inflammatory & Immunosuppressive Signaling**: The S100A8/A9 (calprotectin) heterodimer is a key damage-associated molecular pattern (DAMP) that promotes inflammation and can induce myeloid-derived suppressor cell (MDSC) activity (supported by: 'MDSC', 'Macrophage', 'Adenocarcinoma stem-like cell'). 3) **Granulocyte/Monocyte Lineage Programs**: Enrichment of CSF3R, shared across neutrophils, monocytes, and progenitors (supported by: 'Classical monocyte', 'Granulocyte-monocyte progenitor', 'LMPP'), indicates active granulopoiesis and lineage ambiguity, a hallmark of tumor-educated myeloid cells. 

### 4. Crosstalk & Interactions
The network centers on S100A8/A9 and CSF3R. S100A8/A9 proteins signal through TLR4 and RAGE receptors to activate NF-κB, producing cytokines (e.g., IL-8) that ligate CXCR2, creating a feed-forward loop for myeloid recruitment. CSF3R signaling promotes the expression of S100A8/A9 and survival genes. CLEC4E (a C-type lectin) on 'DC3' and neutrophils can sense DAMPs and further amplify inflammation. FCGR3B (CD16b) mediates immune complex engagement, potentially linking antibody-based immunotherapy (Camrelizumab, an anti-PD1) to neutrophil activation. This crosstalk establishes a self-reinforcing, pro-inflammatory, and immunosuppressive niche. 

### 5. Hypothesis
**What**: The post-treatment NMPR LUSC sample is enriched for an activated, S100A8/A9-high neutrophil/myeloid state with MDSC features. **So What**: This state likely contributes to therapy resistance by creating an immunosuppressive tumor microenvironment. Recruited via CXCR2 and sustained by CSF3R and S100A8/A9 signaling, these cells inhibit anti-tumor immunity through known MDSC mechanisms (e.g., arginase, ROS, PD-L1 expression) and may promote a stem-like niche (as hinted by 'Adenocarcinoma stem-like cell' enrichment), ultimately limiting the efficacy of neoadjuvant chemo-immunotherapy. 

### 6. Narrative Draft
In post-surgical samples from LUSC patients with non-major pathologic response (NMPR) to neoadjuvant camrelizumab plus chemotherapy, we identified a dominant myeloid cell cluster characterized by a core signature of neutrophil markers (SELL, FPR1, FCGR3B, CSF3R, CXCR2) and the alarmins S100A8 and S100A9. Functional enrichment confirms a neutrophil identity but also reveals significant overlap with myeloid-derived suppressor cell (MDSC), monocyte, and dendritic cell subsets, suggesting a plastic or heterogeneous immunosuppressive population. The high expression of the chemokine receptor CXCR2 and the granulopoiesis driver CSF3R indicates active recruitment and local expansion. The persistent enrichment of this pro-inflammatory, S100A8/A9-driven myeloid module post-treatment suggests it may be a key cellular mediator of resistance, potentially dampening adaptive immune responses and fostering a tumor-permissive niche in NMPR patients. 

### 7. Refined Regulatory Network
Key Interactions:
  CSF3R -- S100A8/A9 (activation) - G-CSF signaling via CSF3R is a known transcriptional inducer of S100A8 and S100A9 expression in myeloid cells, central to the observed phenotype.
  S100A8/A9 -- CXCR2 ligands (e.g., CXCL8) (induction) - S100A8/A9 signaling via TLR4/RAGE activates NF-κB, leading to production of CXCR2 ligands (like IL-8), creating an autocrine/paracrine recruitment loop.
  CXCR2 -- Neutrophil Recruitment (mediates) - High CXCR2 expression is a direct mechanism for chemotaxis of this cell population into the tumor, as per 'Neutrophil' enrichment.
  S100A8/A9 -- Immunosuppression (promotes) - S100A8/A9 are functional mediators of MDSC activity, linking the gene signature to the 'Myeloid derived suppressor cell (MDSC)' enrichment.
  FCGR3B -- Inflammation (amplifies) - As an Fc gamma receptor, FCGR3B can engage antibody-opsonized targets, potentially linking Camrelizumab (anti-PD1) to myeloid cell activation in the TME.

**Network Evidence:**
The core functional module is the S100A8-S100A9 heterodimer (calprotectin), a defined protein complex with established DAMP activity. Its connection to CSF3R (a receptor tyrosine kinase) and CXCR2 (a GPCR) forms a signaling axis that explains the recruitment ('Neutrophil'), activation ('Myeloid cell'), and functional phenotype ('MDSC') observed. The presence of CLEC4E, a pattern recognition receptor, and FCGR3B, an Fc receptor, integrates this module with innate immune sensing and potential antibody-dependent effects, respectively. 

---

## Interpretation Result

### Cluster: 21

### 1. Overview
The enrichment results indicate that the cell state is dominated by a secretory epithelial phenotype, specifically reminiscent of lung secretory cells such as Club cells and goblet cells (supported by: Club cell, Secretory cell, Goblet cell, Epithelial cell). The core gene signature (SLPI, WFDC2, CP, KRT18, KRT19) points to active secretion, mucosal defense, and maintenance of epithelial integrity. This profile is observed in a post-treatment, non-major pathologic response (NMPR) LUSC sample, suggesting it may represent a treatment-persistent or adaptive epithelial state. 

### 2. Regulatory Drivers (TFs/Hubs)
No explicit transcription factor enrichment was provided in the top terms. However, the core upregulated genes are known targets of key epithelial and secretory lineage regulators. For instance, SLPI, WFDC2, and KRT19 are regulated by transcription factors like SPDEF and FOXA1/2, which drive secretory cell differentiation in the airway. The strong enrichment for Club and secretory cell identities implies the activity of such master regulators, even if not directly listed, in maintaining this differentiated epithelial program post-therapy. 

### 3. Key Mechanisms
Two major biological themes are identified: 1) **Mucosal Secretion and Innate Defense**: Driven by high expression of secreted proteins SLPI (anti-protease, immunomodulatory), WFDC2 (protease inhibitor), and CP (ceruloplasmin, antioxidant). This module is central to Club/goblet cell function (supported by: Club cell, Secretory cell, Goblet cell). 2) **Epithelial Structural Integrity and Identity**: Defined by cytokeratins (KRT18, KRT19, KRT17) and junction protein CLDN1, marking a luminal epithelial lineage (supported by: Epithelial cell, Luminal cell, Basal cell, Ductal cell). The co-expression of these modules defines a stable, secretory epithelial state. 

### 4. Crosstalk & Interactions
The secretory and structural modules are functionally intertwined. The cytokeratin network (KRT18/KRT19) provides cellular architecture necessary for the polarized secretion of SLPI, WFDC2, and CP. These secreted factors, in turn, may act in a paracrine manner to protect the local epithelial niche from proteolytic damage and oxidative stress, potentially fostering a microenvironment that supports epithelial survival. The presence of both 'Luminal progenitor' and 'Basal cell' enrichments hints at a plastic state, possibly poised for differentiation or repair, regulated by the balance of these structural and secretory programs. 

### 5. Hypothesis
**What**: The post-treatment NMPR LUSC cluster exhibits a strong gene signature of differentiated secretory airway epithelial cells (Club/goblet-like). **So What**: This suggests that in patients with a non-major pathologic response to neoadjuvant chemo-immunotherapy, residual tumor or tumor-adjacent epithelium may adopt a protective, secretory, and relatively quiescent state. This phenotype, characterized by innate defense molecule production (SLPI, WFDC2) and stable epithelial identity (KRT18/19), could contribute to therapy resistance by creating a physically and immunologically shielded niche, limiting drug penetration and immune cell attack. 

### 6. Narrative Draft
In post-surgical samples from LUSC patients with a non-major pathologic response (NMPR) to neoadjuvant camrelizumab plus chemotherapy, we identified a distinct epithelial cell state characterized by markers of secretory function and structural integrity. Functional enrichment analysis revealed a highly significant signature of Club cells and related secretory epithelial types (e.g., goblet cells). This was driven by the coordinated upregulation of secreted factors involved in mucosal immunity (SLPI, WFDC2, CP) and a suite of cytokeratins defining luminal epithelial identity (KRT18, KRT19, KRT17). The persistence of this differentiated, secretion-competent phenotype post-treatment may indicate an adaptive response wherein epithelial cells reinforce barrier defense and survival mechanisms. This state could represent a non-proliferative, therapy-resistant niche that evades eradication by combined chemo-immunotherapy, offering a potential explanation for the observed pathologic response outcome. 

### 7. Refined Regulatory Network
Key Interactions:
  KRT18 -- KRT19 (co-expression/complex) - Core components of the intermediate filament cytoskeleton in simple/epithelial cells; their co-upregulation defines the luminal epithelial identity central to all enriched terms.
  KRT19 -- SLPI (co-regulation) - Both are markers of secretory epithelial lineages (e.g., Club, goblet cells); likely co-regulated by lineage-determining TFs (e.g., SPDEF) to define the secretory cell state.
  SLPI -- WFDC2 (functional synergy) - Both are protease inhibitors secreted by airway epithelial cells; they work in concert to protect mucosal surfaces, forming a core innate defense module in the enriched Club/secretory cell phenotype.
  WFDC2 -- CP (functional synergy) - WFDC2 (protease inhibition) and CP (antioxidant) are co-secreted products that collectively mitigate tissue damage from inflammatory and oxidative stress in the epithelial microenvironment.
  KRT17 -- CLDN1 (structural cooperation) - KRT17 (basal cell cytokeratin) and CLDN1 (tight junction protein) are co-enriched in the 'Basal cell' term; their interaction supports epithelial barrier integrity and may indicate a basal-like layer influence in this state.

**Network Evidence:**
The network centers on two interconnected modules: 1) A **Cytoskeletal Identity Module** comprising KRT18, KRT19, and KRT17, which provides the structural definition for the epithelial and progenitor cell states (Epithelial cell, Luminal cell, Basal cell, Epithelial progenitor). 2) A **Secretory Defense Module** comprising SLPI, WFDC2, and CP, which constitutes the functional output of the Club and secretory cell phenotypes. The co-expression of KRT19 with SLPI and WFDC2 acts as a key nexus, linking the epithelial identity to its secretory function. This integrated network supports the interpretation of a coherent, differentiated epithelial cell state with dual roles in structure and mucosal protection. 

---

## Interpretation Result

### Cluster: 22

### 1. Overview
The functional enrichment analysis of the PostNMPR LUSC single-cell cluster reveals a dominant and highly specific plasma cell/antibody-secreting cell signature. The top enriched terms are exclusively cell-type identity markers (Plasma cell, Plasmacytoid dendritic cell, Plasmablast, B cell subsets, T cell) rather than biological processes or pathways. This indicates the cluster's identity is a terminally differentiated B-lineage cell state, characterized by intense immunoglobulin production and secretion machinery. The high fold-changes of canonical plasma cell genes (JCHAIN, MZB1, DERL3, IGLV3-1, CD79A) strongly support this conclusion. 

### 2. Regulatory Drivers (TFs/Hubs)
Direct transcription factor (TF) enrichment was not provided in the top terms. However, based on the gene expression profile, key regulators of plasma cell differentiation can be inferred. The high expression of CD79A (a component of the B-cell receptor) suggests antecedent signaling through pathways involving TFs like PAX5 (repressed during terminal differentiation) and IRF4/BLIMP1 (encoded by PRDM1, a master regulator of plasma cell fate). The expression of XBP1 target genes (e.g., DERL3, SEC11C) is evident, indicating active engagement of the unfolded protein response (UPR) to handle high secretory load. Thus, the regulatory driver is the IRF4/BLIMP1-XBP1 axis, which orchestrates the shift from a B-cell to a professional secretory plasma cell. 

### 3. Key Mechanisms
Two core biological mechanisms are highlighted by the marker genes: 1) **Immunoglobulin Synthesis and Secretion**: This is the primary function, evidenced by genes for immunoglobulin light chain (IGLV3-1), J chain (JCHAIN) for polymer assembly, and key endoplasmic reticulum (ER) residents for protein processing (DERL3, SEC11C, FKBP11, PRDX4). MZB1 is crucial for IgM assembly and quality control in the ER. 2) **Plasma Cell Identity and Maintenance**: Genes like SLAMF7 (a plasma cell surface receptor) and CD79A (B-cell lineage marker) define the cell's origin and identity. The co-enrichment for 'Plasmacytoid dendritic cell (pDC)' terms is likely a database artifact due to shared expression of certain ER/stress genes (ITM2C, MZB1, JCHAIN) between professional secretory cells, but the full profile is definitive for plasma cells. 

### 4. Crosstalk & Interactions
The network is intrinsically coordinated rather than exhibiting crosstalk between disparate pathways. The IRF4/BLIMP1-driven differentiation program directly activates XBP1, which then upregulates a suite of ER-associated protein processing genes (DERL3, SEC11C) to expand the secretory capacity. This creates a feed-forward loop where commitment to antibody production necessitates UPR activation. The surface receptor SLAMF7 may provide external survival or positioning signals back to the core plasma cell program. The presence of CD79A connects this mature state to its B-cell receptor signaling history. 

### 5. Hypothesis
**What**: A distinct cluster in post-treatment, non-major pathologic response (NMPR) LUSC tumors is composed of plasma cells exhibiting a strong immunoglobulin synthesis and secretion signature. **So What**: The persistence or recruitment of antibody-secreting plasma cells in tumors that did not achieve a major response to neoadjuvant chemo-immunotherapy (Camrelizumab) suggests a potential role for humoral immunity that is insufficient for tumor clearance or may even be involved in pro-tumorigenic processes (e.g., producing autoantibodies or immunosuppressive factors). This plasma cell response could represent a compartmentalized, non-cytotoxic immune reaction distinct from the cell-mediated responses (e.g., CD8+ T cell expansion) typically associated with pathologic response (MPR/pCR). 

### 6. Narrative Draft
In the post-treatment tumor microenvironment of non-responder (NMPR) LUSC patients, we identified a cell cluster unequivocally defined as plasma cells, as supported by enrichment for canonical markers (Plasma cell, Plasmablast) and high expression of genes central to immunoglobulin production (JCHAIN, MZB1, IGLV3-1) and ER processing (DERL3, SEC11C). This terminal B-cell differentiation state, driven by the BLIMP1-XBP1 axis, indicates active humoral immunity within the residual tumor. While plasma cells can contribute to anti-tumor responses via antibody-dependent mechanisms, their prominence in NMPR samples, as opposed to MPR/pCR, raises the hypothesis that this specific B-cell response may be ineffective or altered in function. This finding underscores the need to dissect the specificity and regulatory context of tumor-infiltrating plasma cells to understand their impact on therapy resistance. 

### 7. Refined Regulatory Network
Key Interactions:
  PRDM1 (BLIMP1) -- XBP1 (activation) - Master regulator of plasma cell differentiation that induces the unfolded protein response master regulator XBP1 to handle increased immunoglobulin secretion.
  XBP1 -- DERL3 (activation) - DERL3 is a direct target gene of the XBP1-driven unfolded protein response, essential for ER-associated degradation (ERAD).
  XBP1 -- SEC11C (activation) - SEC11C is involved in protein translocation/sec61 complex; its expression is coupled to secretory demand and UPR.
  MZB1 -- Immunoglobulin M (IgM) (binding/chaperone) - MZB1 is an ER-resident chaperone specifically facilitating IgM assembly and secretion, a core function of this plasma cell cluster.
  JCHAIN -- Immunoglobulin A/G/M (binding/polymerization) - JCHAIN is essential for the polymerization of IgA and IgM, defining the type of antibody being secreted.
  SLAMF7 -- Plasma Cell Survival (signaling) - SLAMF7 is a plasma cell surface receptor that can deliver pro-survival signals, maintaining the identified cell state.

**Network Evidence:**
The network centers on the functional module of immunoglobulin biosynthesis and secretion. The key complex is the **Immunoglobulin molecule itself**, assembled with a light chain (IGLV3-1) and a J chain (JCHAIN). This assembly is chaperoned in the ER by **MZB1**. The high secretory demand activates the **XBP1-mediated Unfolded Protein Response (UPR) module**, which upregulates ERAD components like **DERL3** and translocon components like **SEC11C**. This coherent module explains the extreme upregulation of the marker genes and confirms the cell's primary role as a professional antibody factory. The surface marker **SLAMF7** and the lineage marker **CD79A** form an identity/signaling module that contextualizes this factory within the immune system. 

---

## Interpretation Result

### Cluster: 23

### 1. Overview
The enrichment analysis identifies a dominant ciliated cell signature in the post-treatment, non-major pathologic response (NMPR) LUSC sample. The top enriched terms are exclusively cell type annotations ('Ciliated cell', 'Ciliated epithelial cell', 'Prehypertrophic chondrocyte'), not signaling pathways or upstream regulators. The ten marker genes defining this cluster are all highly upregulated and are canonical structural and functional components of motile cilia. This indicates the cluster represents a population of normal, differentiated ciliated epithelial cells, likely from adjacent or entrapped non-malignant airway tissue within the tumor microenvironment. 

### 2. Regulatory Drivers (TFs/Hubs)
No transcription factors or master regulators were identified in the provided enrichment list. The signature is driven by terminal differentiation markers, not upstream regulatory programs. Key structural genes like RSPH1 (radial spoke head component), PIFO (ciliary basal body protein), and TPPP3 (tubulin polymerization promoter) are effectors of the ciliated phenotype. Their expression is likely governed by established ciliogenesis regulators (e.g., FOXJ1, MCIDAS, RFX family TFs) that are not present in the provided gene list, implying these master regulators were active earlier in differentiation and are no longer highly expressed in this mature cell state. 

### 3. Key Mechanisms
The core mechanism is the structural and functional specialization for mucociliary clearance. This is supported by three interconnected biological modules: 1) **Axonemal Dynein Arm Assembly** (implied by genes like C11orf88, C9orf24, C1orf194, which are dynein axonemal assembly factors), essential for ciliary beating; 2) **Radial Spoke and Central Pair Apparatus** (RSPH1, PIFO), critical for the regulation and symmetry of ciliary stroke; and 3) **Microtubule Stabilization and Organization** (TPPP3, TSPAN1), which provides the structural backbone of the ciliary axoneme. The weak link to 'Prehypertrophic chondrocyte' is likely an artifact of shared expression of cytoskeletal organization genes (TPPP3, CAPS) between distinct cell types. 

### 4. Crosstalk & Interactions
Within this ciliary module, crosstalk is structural and co-dependent rather than signaling-based. The assembly factors (C11orf88, C9orf24, C1orf194) are required for the proper integration of dynein motors onto the microtubule scaffold built and stabilized by TPPP3. The radial spoke head protein RSPH1 must interact with the central pair apparatus (not in the list) to convert dynein-driven microtubule sliding into coordinated, rhythmic bending. The network functions as an integrated mechanical machine, where the absence of any key component can lead to ciliary dyskinesia. 

### 5. Hypothesis
**What:** The most distinct cell state in post-treatment NMPR LUSC is a population of normal, terminally differentiated ciliated epithelial cells. **So What:** The prominence of this non-malignant, non-immune stromal population in the post-treatment NMPR sample suggests a tumor microenvironment with preserved or possibly expanded normal airway structures, potentially indicative of a treatment effect that eliminates tumor cells but leaves architecturally normal lung tissue. Alternatively, it may reflect sampling of adjacent non-involved airway. Its presence argues against a treatment-driven, inflamed, or proliferative residual tumor ecosystem in this specific NMPR case, highlighting the cellular heterogeneity of post-treatment samples. 

### 6. Narrative Draft
Single-cell transcriptomic analysis of a post-surgical, non-major pathologic response (NMPR) LUSC sample following neoadjuvant camrelizumab and chemotherapy revealed a dominant cluster characterized by a robust ciliated cell signature (supported by: Ciliated cell, Ciliated epithelial cell). This signature was defined by the high expression of canonical ciliary genes, including axonemal dynein assembly factors (C11orf88, C9orf24, C1orf194), radial spoke components (RSPH1, PIFO), and microtubule-associated proteins (TPPP3, TSPAN1). The absence of enrichment for proliferative, immune, or stress-response pathways indicates this population represents terminally differentiated, non-cycling epithelial cells. In the context of post-treatment NMPR, the prominence of this normal epithelial phenotype may reflect the sampling of residual non-malignant airway tissue within the resection specimen, suggesting a microenvironment where treatment has eliminated tumor cells without inducing a profound stromal remodeling response in this particular niche. 

### 7. Refined Regulatory Network
Key Interactions:
  TPPP3 -- Microtubule cytoskeleton (stabilizes) - TPPP3 is a tubulin polymerization-promoting protein essential for axonemal microtubule assembly, forming the core scaffold for all other ciliary components.
  C11orf88 -- Dynein complex (assembles) - C11orf88 (DNAAF3) is a cytoplasmic dynein axonemal assembly factor required for the pre-assembly of dynein arms before their transport into the cilium.
  RSPH1 -- Axonemal radial spoke (component_of) - RSPH1 is a core structural component of the radial spoke head, a complex that mechanically couples the central pair apparatus to the dynein arms to regulate beating.
  PIFO -- Basal body (localizes_to) - PIFO is a basal body protein required for the correct docking and orientation of the basal body, the foundation from which the axoneme nucleates.
  C11orf88/C9orf24/C1orf194 -- Dynein arm (assembly_module) - These genes (DNAAF3, DNAAF1, DNAAF4) form a functional module of dynein assembly factors that work cooperatively in the cytoplasm to build functional dynein motor complexes.

**Network Evidence:**
The provided gene set constitutes a coherent functional module for motile cilium assembly and function. The network is centered on the axonemal microtubule scaffold (stabilized by TPPP3). Key protein complexes include: 1) The **cytoplasmic dynein assembly module** (C11orf88/DNAAF3, C9orf24/DNAAF1, C1orf194/DNAAF4), which are not part of the final cilium but are essential chaperones for constructing the dynein arm complexes that power ciliary beating. 2) The **radial spoke head complex**, represented by RSPH1, which is a definitive marker of motile (not primary) cilia and is part of a multi-protein complex that transduces mechanical signals. The presence of both assembly factors and structural components confirms this signature represents actively functioning ciliated cells, not just cells expressing a few ciliary genes. 

---

